WO2020034939A1 - 一种化学发光分析方法及其应用 - Google Patents

一种化学发光分析方法及其应用 Download PDF

Info

Publication number
WO2020034939A1
WO2020034939A1 PCT/CN2019/100341 CN2019100341W WO2020034939A1 WO 2020034939 A1 WO2020034939 A1 WO 2020034939A1 CN 2019100341 W CN2019100341 W CN 2019100341W WO 2020034939 A1 WO2020034939 A1 WO 2020034939A1
Authority
WO
WIPO (PCT)
Prior art keywords
microspheres
group
polysaccharide
tested
sample
Prior art date
Application number
PCT/CN2019/100341
Other languages
English (en)
French (fr)
Inventor
杨阳
康蔡俊
赵卫国
刘宇卉
李临
Original Assignee
博阳生物科技（上海）有限公司
北京科美生物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 博阳生物科技（上海）有限公司, 北京科美生物技术有限公司 filed Critical 博阳生物科技（上海）有限公司
Publication of WO2020034939A1 publication Critical patent/WO2020034939A1/zh

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/75—Systems in which material is subjected to a chemical reaction, the progress or the result of the reaction being investigated
    • G01N21/76—Chemiluminescence; Bioluminescence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles

Definitions

  • the invention belongs to the technical field of chemiluminescence analysis, and particularly relates to a chemiluminescence analysis method and application thereof.
  • Chemiluminescence analysis is a method that uses light waves emitted by chemiluminescent substances for detection.
  • Chemiluminescent substances are used as markers in nucleic acid detection and immunoassay.
  • a molecule in a specific binding pair can be combined with a luminescent substance through a variety of ways to form a luminescent microsphere composition.
  • the microsphere composition can react with the test object (another molecule in the specific binding pair) in the sample, and is distributed in the solid phase and the liquid phase, and the distribution ratio is related to the amount of the test object. By measuring the amount of luminescence in the solid or liquid phase, the corresponding concentration of the detected substance in the sample can be obtained.
  • the technical problem to be solved by the present invention is to address the shortcomings of the prior art, and provide a chemiluminescence analysis method, which has both ultra-high sensitivity and a wide detection range. In addition, this method can also shorten the detection time.
  • the present invention provides a chemiluminescence analysis method, which analyzes and determines the intensity of chemiluminescence signals generated by the reaction between at least two kinds of acceptor microspheres with different particle sizes and reactive oxygen species in a sample to be measured. Whether to include the target molecule and / or the concentration of the target molecule.
  • the method analyzes and determines whether the test sample contains the test sample by detecting the intensity of the chemiluminescence signal generated by the reaction between two types of acceptor microspheres with different particle sizes and reactive oxygen species in the test sample.
  • the concentration of the target molecule and / or the target molecule to be measured is a parameter that determines whether the test sample contains the test sample.
  • the difference in particle size between the two acceptor microspheres with different particle sizes is not less than 100 nm; preferably not less than 150 nm; more preferably not less than 200 nm.
  • the particle size ratio of the two acceptor microspheres with different particle sizes is selected from 1: (1.1-10); preferably selected from 1: (2-8); more preferably From 1: (3-6).
  • the use concentration of the receptor microsphere is 1 ug / mL-1000 ug / mL; preferably 10 ug / mL-500 ug / mL; more preferably 10 ug / mL-250 ug / mL.
  • the test sample further includes a donor microsphere, and the donor microsphere can generate active oxygen under an excited state.
  • the method is a homogeneous chemiluminescence analysis method.
  • the method includes the following steps:
  • step S2 Use energy or an active chemical to contact the sample to be measured obtained in step S1 to stimulate the donor to generate active oxygen;
  • test sample contains the target molecule and / or the target molecule by detecting the intensity of the chemiluminescence signal generated by the reaction between at least two kinds of acceptor microspheres with different particle sizes and active oxygen in the sample to be tested concentration.
  • the sample to be tested is diluted with a diluent and then reacted.
  • the method analyzes and determines whether the test sample contains the test sample by detecting the intensity of the chemiluminescence signal generated by the reaction between three kinds of acceptor microspheres with different particle sizes and reactive oxygen species in the test sample.
  • the concentration of the target molecule and / or the target molecule to be measured is a parameter that determines whether the test sample contains the test sample.
  • the detection wavelength of the chemiluminescence signal is 520-620 nm.
  • laser irradiation is performed with red excitation light at 600 to 700 nm.
  • the acceptor microsphere includes a luminescent composition and a matrix, and the luminescent composition is filled in the matrix and / or coated on the surface of the matrix.
  • the luminescent composition is capable of reacting with active oxygen to generate a detectable chemiluminescent signal, which comprises a chemiluminescent compound and a metal chelate.
  • the chemiluminescent compound is selected from olefin compounds, preferably from dimethylthiophene, dibutanedione compound, dioxane, enol ether, enamine, 9- Alkylene xanthane, 9-alkylene-N-9,10 dihydroacridine, aryl etherene, arylimidazole, and gloss derivatives and their derivatives, more preferably selected from dimethylthiophene and its derivatives derivative.
  • olefin compounds preferably from dimethylthiophene, dibutanedione compound, dioxane, enol ether, enamine, 9- Alkylene xanthane, 9-alkylene-N-9,10 dihydroacridine, aryl etherene, arylimidazole, and gloss derivatives and their derivatives, more preferably selected from dimethylthiophene and its derivatives derivative.
  • the metal of the metal chelate is a rare earth metal or a Group VIII metal, preferably selected from the group consisting of rhenium, osmium, osmium, osmium, osmium, and ruthenium, and more preferably selected from osmium.
  • the metal chelate comprises a chelating agent selected from the following: MTTA, NHA, BHHT, BHHCT, DPP, TTA, NPTTA, NTA, TOPO, TPPO, BFTA, 2, 2 -Dimethyl-4-perfluorobutyryl-3-butanone (fod), 2,2'-bipyridyl (bpy), bipyridylcarboxylic acid, aza crown ether, aza-hole ligand and Octylphosphine oxide and their derivatives.
  • a chelating agent selected from the following: MTTA, NHA, BHHT, BHHCT, DPP, TTA, NPTTA, NTA, TOPO, TPPO, BFTA, 2, 2 -Dimethyl-4-perfluorobutyryl-3-butanone (fod), 2,2'-bipyridyl (bpy), bipyridylcarboxylic acid, aza crown ether, aza-hole
  • the luminescent compound is a derivative of dimethylthiophene, and the metal chelate is a europium chelate.
  • the matrix is selected from the group consisting of tapes, sheets, rods, tubes, wells, microtiter plates, beads, particles and microspheres; preferably beads and microspheres.
  • the matrix is magnetic or non-magnetic particles.
  • the materials of the substrates of the receptor microspheres with different particle sizes are the same or different.
  • the matrix material is selected from the group consisting of natural, synthetic, or modified naturally occurring polymers, including but not limited to: agarose, cellulose, nitrocellulose, cellulose acetate, Polyvinyl chloride, polystyrene, polyethylene, polypropylene, poly (4-methylbutene), polyacrylamide, polymethacrylate, polyethylene terephthalate, nylon, polybutyrate Or polyacrylate.
  • natural, synthetic, or modified naturally occurring polymers including but not limited to: agarose, cellulose, nitrocellulose, cellulose acetate, Polyvinyl chloride, polystyrene, polyethylene, polypropylene, poly (4-methylbutene), polyacrylamide, polymethacrylate, polyethylene terephthalate, nylon, polybutyrate Or polyacrylate.
  • the matrix is an aldehyde-based latex microsphere; preferably an aldehyde-based polystyrene latex microsphere.
  • a biologically active substance is directly connected to the surface of the matrix, and the biologically active substance can specifically bind to a target molecule to be detected.
  • the surface of the substrate is coated with a coating layer, and the surface of the coating layer is connected with a biologically active substance, and the biologically active substance can specifically bind to a target molecule to be detected.
  • the coating in the coating layer is selected from a polysaccharide, a polymer, or a biomacromolecule, and is preferably a polysaccharide.
  • the surface of the matrix is coated with a coating of at least two continuous polysaccharide layers, wherein the first polysaccharide layer is spontaneously associated with the second polysaccharide layer.
  • each of the continuous polysaccharide layers is spontaneously associated with each of the previous polysaccharide layers.
  • the polysaccharide has a side group functional group, and the functional group of the continuous polysaccharide layer has an opposite charge to the functional group of the previous polysaccharide layer.
  • the polysaccharide has a pendant functional group, and the continuous layer of the polysaccharide is reacted with the functional group of the continuous layer and the functional group of the previous layer by The former polysaccharide layer is covalently linked.
  • the functional group of the continuous polysaccharide layer alternates between an amine functional group and an amine-reactive functional group.
  • the amine-reactive functional group is an aldehyde group or a carboxyl group.
  • the first polysaccharide layer is spontaneously associated with the carrier.
  • the outermost polysaccharide layer of the coating has at least one pendant functional group.
  • the side functional group of the outermost polysaccharide layer of the coating is selected from at least one of an aldehyde group, a carboxyl group, a thiol group, an amino group, a hydroxyl group, and a maleamine group; From aldehyde and / or carboxyl.
  • the side group functional group of the outermost polysaccharide layer of the coating is directly or indirectly connected to the bioactive substance.
  • the polysaccharide is selected from a carbohydrate containing three or more unmodified or modified monosaccharide units; preferably selected from dextran, starch, glycogen, inulin, fruit Glycans, mannans, agaroses, galactans, carboxydextran and aminodextran; more preferably selected from dextran, starch, glycogen and polyribose.
  • the matrix diameters of the receptor microspheres with different particle diameters are the same.
  • the size of the matrix of the acceptor microspheres with different particle sizes is different.
  • the active oxygen is singlet oxygen.
  • a chemiluminescence analyzer using the method according to the first aspect of the present invention to detect the presence and / or concentration of a target molecule in a sample to be tested.
  • the chemiluminescence analyzer includes at least the following parts:
  • An incubation module which is used to provide a suitable temperature environment for a chemiluminescence reaction after mixing a sample to be measured and at least two kinds of acceptor microspheres with different particle diameters;
  • a processor which determines whether a target molecule to be tested exists in the sample to be tested and / or a concentration of the target molecule to be tested in the sample to be tested according to the situation of the chemiluminescence signal detected by the detection module.
  • a third aspect of the present invention provides a method according to the first aspect of the present invention and / or a chemiluminescence analyzer according to the second aspect of the present invention for detecting myocardial injury markers including cTnI and / or including Application of procalcitonin, including markers of inflammation.
  • the beneficial effect of the present invention is that the chemiluminescence analysis method of the present invention includes adding at least two kinds of acceptor microspheres with different particle diameters (small-size acceptor microspheres and large-particle acceptor microspheres) Body microspheres), because the receiver microspheres with small particle diameter can widen the detection range, and the receiver microspheres with large particle diameter can improve the detection sensitivity, so that the detection performance of the method of the present invention is greatly improved compared with the prior art. It has super high sensitivity and wide detection range.
  • the detection time can also be shortened when the method of the present invention is used for detection, and the reaction speed is improved.
  • FIG. 1 is a Gaussian distribution curve diagram of the aldehyde-based polystyrene latex microspheres prepared in Example 3.
  • FIG. 1 is a Gaussian distribution curve diagram of the aldehyde-based polystyrene latex microspheres prepared in Example 3.
  • FIG. 2 is a Gaussian distribution curve diagram of the aldehyde-based polystyrene latex microspheres filled with the luminescent composition prepared in Example 3.
  • FIG. 2 is a Gaussian distribution curve diagram of the aldehyde-based polystyrene latex microspheres filled with the luminescent composition prepared in Example 3.
  • FIG. 3 is a Gaussian distribution diagram of the dextran-coated aldehyde-containing polystyrene latex microspheres coated with a luminescent composition prepared in Example 3.
  • Example 4 is a Gaussian distribution diagram of the acceptor microspheres having an average particle diameter of about 250 nm prepared in Example 3.
  • FIG. 5 is a Gaussian distribution diagram of the acceptor microspheres having a particle size of about 110 nm prepared in Example 3.
  • FIG. 5 is a Gaussian distribution diagram of the acceptor microspheres having a particle size of about 110 nm prepared in Example 3.
  • FIG. 6 is a Nicomp distribution diagram of the acceptor microspheres having a particle size of about 110 nm prepared in Example 3.
  • FIG. 6 is a Nicomp distribution diagram of the acceptor microspheres having a particle size of about 110 nm prepared in Example 3.
  • FIG. 7 is a Gaussian distribution diagram of the acceptor microspheres having a particle size of about 350 nm prepared in Example 3.
  • FIG. 7 is a Gaussian distribution diagram of the acceptor microspheres having a particle size of about 350 nm prepared in Example 3.
  • FIG. 8 is a Nicomp distribution diagram of the acceptor microspheres having a particle diameter of about 350 nm prepared in Example 3.
  • FIG. 8 is a Nicomp distribution diagram of the acceptor microspheres having a particle diameter of about 350 nm prepared in Example 3.
  • FIG. 9 is a Gaussian distribution diagram of the particle size distribution of the mixed acceptor microspheres in Example 4.
  • FIG. 9 is a Gaussian distribution diagram of the particle size distribution of the mixed acceptor microspheres in Example 4.
  • FIG. 10 is a Nicomp distribution diagram of the particle size distribution of the mixed acceptor microspheres in Example 4.
  • FIG. 10 is a Nicomp distribution diagram of the particle size distribution of the mixed acceptor microspheres in Example 4.
  • active oxygen in the present invention refers to a general term for a substance composed of oxygen in the body or in the natural environment, which contains oxygen and is active in nature. It is mainly an excited oxygen molecule, including superoxide, an electron reduction product of oxygen. Anions (O 2 ⁇ -), two-electron reduction products hydrogen peroxide (H 2 O 2 ), three-electron reduction products hydroxyl radicals ( ⁇ OH), nitric oxide and singlet oxygen (1O 2 ), and the like.
  • the term "receptor microsphere” refers to a nanomicrosphere capable of reacting with active oxygen to generate a detectable chemiluminescence signal, which may also be referred to as an oxygen-receiving microsphere or a light-emitting microsphere.
  • the acceptor microspheres may be polymer particles filled with a functional group to form a polymer particle filled with a light emitting composition, and the light emitting composition includes a chemiluminescent compound capable of reacting with active oxygen.
  • the chemiluminescent compound undergoes a chemical reaction with active oxygen to form an unstable metastable intermediate, which can be decomposed and emit light simultaneously or subsequently.
  • Typical examples of these materials include, but are not limited to, enol ethers, enamines, 9-alkylidene xanthan gum, 9-alkylidene-N-alkylacridine, aryl etherene, dioxyethylene, dimethyl ether Thiophene, aryl imidazole or gloss fine.
  • the "chemiluminescent compound” is a compound called a label, which can undergo a chemical reaction to cause light emission, for example, by being converted into another compound formed in an electronically excited state.
  • the excited state can be a singlet state or a triplet excited state.
  • the excited state can relax to the ground state and emit light directly, or it can restore itself to the ground state by transmitting the excitation energy to the emitting energy acceptor. During this process, the energy acceptor microspheres will be transitioned to an excited state and emit light.
  • the chemiluminescent compound can be bound to a specific binding partner member, which can directly or indirectly bind to a target molecule or a test component under test, and the concentration of the test component is affected by the presence of the target molecule to be tested.
  • a specific binding partner member which can directly or indirectly bind to a target molecule or a test component under test, and the concentration of the test component is affected by the presence of the target molecule to be tested.
  • “capable of binding directly or indirectly” means that the specified entity can specifically bind to the entity (directly), or the specified entity can specifically bind to a specific binding pair member, or has two Or more (indirectly) a complex of a specific binding partner capable of binding other entities.
  • the "specific binding pair member" of the present invention is selected from (1) a small molecule and a binding partner for the small molecule, and (2) a large molecule and a binding partner for the large molecule.
  • the active oxygen may be provided by a “donor microsphere”, and the donor microsphere is a nanomicrosphere capable of generating active oxygen in an excited state.
  • the donor microspheres can be coated with functional groups to form polymer particles filled with a photosensitive compound, which can generate singlet oxygen under light excitation.
  • the photosensitive microspheres can also be called Oxygen-supplying microspheres or photosensitive microspheres.
  • the surface of the donor microsphere may have a hydrophilic aldehyde dextran, and the interior is filled with a photosensitizer.
  • the photosensitizer may be a photosensitizer known in the art, preferably a compound that is relatively light stable and does not effectively react with singlet oxygen, and non-limiting examples thereof include compounds such as methylene blue, rose red, porphyrin, and phthalocyanine, And derivatives of these compounds with 1-50 atomic substituents, which are used to make these compounds more lipophilic or more hydrophilic, and / or as linkers attached to specific binding pair members group.
  • the donor microspheres can also be filled with other sensitizers, non-limiting examples of which are certain compounds that catalyze the conversion of hydrogen peroxide to singlet oxygen and water.
  • Examples of other donors include: 1,4-dicarboxyethyl-1,4-naphthalene endoxide, 9,10-diphenylanthracene-9,10-endoperoxide, etc., heating these compounds or These compounds directly absorb light and release reactive oxygen species, such as singlet oxygen.
  • the "matrix” according to the present invention can be any size, it can be organic or inorganic, it can be expandable or non-expandable, it can be porous or non-porous, it can have any density, However, it preferably has a density close to that of water, and is preferably capable of floating in water and composed of a transparent, partially transparent or opaque material.
  • the matrix may or may not be electrically charged, and when electrically charged, it is preferably negatively charged.
  • the matrix can be a solid (e.g., polymer, metal, glass, organic and inorganic materials such as minerals, salts and diatoms), small oil droplets (e.g., hydrocarbon, fluorocarbon, siliceous fluid), vesicles (e.g., Synthetic such as phospholipids, or natural such as cells, and cellular organs).
  • the matrix can be latex particles or other particles containing organic or inorganic polymers, lipid bilayers such as liposomes, phospholipid vesicles, small oil droplets, silicon particles, metal sols, cells and microcrystalline dyes.
  • Matrices are generally versatile or capable of binding to a donor or acceptor through specific or non-specific covalent or non-covalent interactions.
  • Typical functional groups include carboxylic acid, acetaldehyde, amino, cyano, vinyl, hydroxyl, mercapto, and the like.
  • a matrix suitable for use in the present invention is aldehyde-based polystyrene latex microspheres.
  • the photosensitizer and / or chemiluminescent compound can be selected to be dissolved, or non-covalently bound to the surface of the particle.
  • these compounds are preferably hydrophobic to reduce their ability to dissociate from the particles so that both compounds can bind to the same particles.
  • the term “particle diameter” in the present invention refers to the average particle diameter of the luminescent microspheres, and it is measured by a conventional particle size meter.
  • the "receptor microspheres" of the present invention include at least a matrix, a luminescent composition, and a bioactive molecule, and preferably also a coating layer; the luminescent composition may be filled in the matrix and / or coated on the surface of the matrix.
  • the receptor microsphere does not include a coating, the bioactive substance is directly connected to the surface of the substrate.
  • the receptor microsphere includes a coating layer, the coating layer is coated on the surface of the substrate, and the outermost layer of the coating layer is connected with a bioactive active substance.
  • the "average particle diameter of the acceptor microspheres" in the present invention refers to the average particle diameter of the acceptor microspheres after being connected and / or coated with the corresponding substance.
  • the particle diameter of the matrix in the receptor microspheres of different particle diameters may be the same or different, as long as the particle diameters of the receptor microspheres finally formed are different.
  • the most preferred technical solution of the present invention is that the receptors of different particle diameters
  • the particle size of the matrix in the bulk microspheres is also different.
  • sample to be tested refers to a mixture containing the target molecule to be tested or suspected of containing the target molecule to be tested.
  • Test samples that can be used in the present disclosure include body fluids, such as blood (which can be anticoagulated commonly seen in collected blood samples), plasma, serum, urine, semen, saliva, cell culture, tissue extraction Things.
  • Other types of samples to be tested include solvents, seawater, industrial water samples, food samples, environmental samples such as soil or water, plant materials, eukaryotic cells, bacteria, plasmids, viruses, fungi, and cells from prokaryotes.
  • the sample to be tested can be diluted with diluent as needed before use. For example, in order to avoid the HOOK effect, the sample to be tested can be diluted with a diluent before detection on the machine, and then tested on a testing instrument.
  • target molecule to be detected refers to a substance in a sample to be detected during detection.
  • One or more substances with specific binding affinity to the target molecule to be detected will be used to detect the target molecule.
  • the target molecule to be detected may be a protein, a peptide, an antibody, or a hapten capable of binding to the antibody.
  • the target molecule to be detected may be a nucleic acid or an oligonucleotide bound to a complementary nucleic acid or an oligonucleotide.
  • the target molecule to be detected may be any other substance that can form a specific binding pair member.
  • Examples of other typical target molecules to be tested include: drugs such as steroids, hormones, proteins, glycoproteins, mucins, nucleoproteins, phosphoproteins, drugs of abuse, vitamins, antibacterials, antifungals, antivirals, Purines, antitumor agents, amphetamines, aza compounds, nucleic acids and prostaglandins, and metabolites of any of these drugs; pesticides and their metabolites; and receptors.
  • Analytes also include cells, viruses, bacteria, and fungi.
  • sample to be tested in the present invention refers to a mixed liquid to be tested containing multi-components such as the sample to be tested, the acceptor microspheres and the donor microspheres according to the present invention before the detection and analysis on the machine.
  • antibody as used in the present invention is used in the broadest meaning and includes antibodies of any isotype, antibody fragments that retain specific binding to the antigen, including but not limited to Fab, Fv, scFv, and Fd fragments, and chimeric antibodies , A humanized antibody, a single chain antibody, a bispecific antibody, and a fusion protein comprising an antigen-binding portion of the antibody and a non-antibody protein.
  • the antibody can be further associated with other parts, such as specific binding pair members, such as biotin or streptavidin (a member of the biotin-streptavidin specific binding pair member), etc. Conjugation.
  • antigen in the present invention refers to a substance capable of stimulating the body to produce an immune response, and capable of binding to immune response product antibodies and sensitized lymphocytes in vivo and in vitro to generate an immune effect.
  • binding refers to a direct association between two molecules caused by interactions such as covalent, electrostatic, hydrophobic, ionic, and / or hydrogen bonding, including, but not limited to, interactions such as salt bridges and water bridges. .
  • the term “specific binding” in the present invention refers to the mutual discrimination and selective binding reaction between two substances, and from the perspective of the three-dimensional structure, it is the conformational correspondence between the corresponding reactants.
  • the detection method of the specific binding reaction includes, but is not limited to, a double antibody sandwich method, a competition method, a neutralization competition method, an indirect method or a capture method.
  • homogeneous corresponding to the present invention is “homogeneous”, which means that detection can be performed without separating the bound antigen-antibody complex and the remaining free antigen or antibody.
  • C.V value of the particle size distribution variation coefficient in the present invention refers to the variation coefficient of the particle size in the Gaussian distribution in the detection result of the nanometer particle size analyzer.
  • Nicomp distribution in the present invention refers to an algorithmic distribution in the American PSS nano particle size analyzer NICOMP. Compared with the Gaussian unimodal algorithm, the Nicomp multimodal algorithm has unique advantages for the analysis of multi-component, liquid dispersion systems with uneven particle size distribution and the stability analysis of colloidal systems.
  • the first aspect of the present invention relates to a chemiluminescence analysis method, which analyzes and determines whether a chemiluminescent signal intensity generated by the reaction between at least two kinds of acceptor microspheres with different particle diameters and reactive oxygen species in a sample to be tested is analyzed. Contains the target molecule and / or the concentration of the target molecule.
  • the method analyzes and determines whether the test sample contains the test sample by detecting the intensity of the chemiluminescence signal generated by the reaction between two types of acceptor microspheres with different particle sizes and reactive oxygen species in the test sample.
  • the concentration of the target molecule and / or the target molecule to be measured is a parameter that determines whether the test sample contains the test sample.
  • the difference in particle size between the two acceptor microspheres with different particle sizes is not less than 100 nm; preferably not less than 150 nm; more preferably not less than 200 nm. In some specific embodiments of the present invention, the difference between the particle diameters of the two acceptor microspheres with different particle diameters is not less than 100 nm, 130 nm, 150 nm, 170 nm, 190 nm, 200 nm, 220 nm, 240 nm, or 250 nm.
  • the particle size ratio of the two acceptor microspheres with different particle sizes is selected from 1: (1.1-10); preferably selected from 1: (2-8); more preferably From 1: (3-6). In some specific embodiments of the present invention, the particle size ratio of the two types of acceptor microspheres with different particle sizes is selected from 1: 1.5, 1: 2, 1: 2.7, 1: 3, 1: 3.2, 1 : 3.75, 1: 4, 1: 5, or 1: 6.
  • the particle size of one of the acceptor microspheres is selected from 50 nm to 300 nm, and the particle size of the other acceptor microsphere is selected from 200 nm to 400 nm.
  • one of the acceptor microspheres has a particle size selected from 50nm, 80nm, 110nm, 140nm, 170nm, 200nm, or 300nm, and the other acceptor microsphere has a particle size selected from 200nm, 250nm, 300nm, 350nm, or 400nm .
  • the particle size of one of the acceptor microspheres is selected from 50 nm to 200 nm, and the particle size of the other acceptor microsphere is selected from 200 nm to 350 nm.
  • the particle size of one of the acceptor microspheres is selected from 80 nm to 150 nm, and the particle size of the other acceptor microsphere is selected from 220 nm to 350 nm.
  • the size of the particle size of the acceptor microspheres should be able to produce a uniform and stable latex solution.
  • the particle size of the acceptor microspheres that can meet this requirement should be in the nanometer range. Therefore, the upper limit of the particle size of the large-size acceptor microspheres is to produce a stable latex solution, and it is generally appropriate to select about 300 nm.
  • the coating and cleaning of the receptor microspheres must be able to be performed under the existing technical conditions to meet the production of reagents.
  • the method of the present invention controls the particle size of the receptor microspheres in the microsphere composition used, and then controls the amount of bioactive substances (such as antibodies / antigens) on the surface of each receptor microsphere (small particle size microspheres).
  • bioactive substances such as antibodies / antigens
  • the specific surface area is large, the number of molecules reported on the surface of the unit mass microsphere is large, the specific surface area of the large particle size microsphere is small, and the number of molecules reported on the surface of the unit mass microsphere is small), thereby improving the detection sensitivity and expanding the detection range.
  • the small diameter of the acceptor microspheres with small particle diameter the activation efficiency of the single-line oxygen generated by the donor microspheres is improved, and the luminous efficiency of the acceptor microspheres can also be improved.
  • the use concentration of the receptor microsphere is 1 ug / mL-1000 ug / mL; preferably 10 ug / mL-500 ug / mL, and more preferably 50 ug / mL-250 ug / mL.
  • the used concentration of the receptor microspheres is determined by the concentration of different target molecules in the blood and the characteristics of the target molecules to be measured.
  • the test sample further includes a donor microsphere, and the donor microsphere can generate active oxygen under an excited state.
  • the method is a homogeneous chemiluminescence analysis method.
  • the method includes the following steps:
  • step S2 Use energy or an active chemical to contact the sample to be measured obtained in step S1 to stimulate the donor to generate active oxygen;
  • test sample contains the target molecule and / or the target molecule by detecting the intensity of the chemiluminescence signal generated by the reaction between at least two kinds of acceptor microspheres with different particle diameters and active oxygen in the sample to be tested. concentration.
  • the particle size distribution coefficient of variation CV of the receptor microspheres in the reagent a may be 5%, 6%, 7%, 8%, 9%, 10%, 11% , 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 25%, 30%, 35% or 40%, etc.
  • coefficient of variation C.V of the particle size distribution of the acceptor microspheres according to the present invention refers to the value of the coefficient of variation C.V of the particle size distribution of the receptor microspheres after coating with the desired substance.
  • step S1 after the sample to be measured is mixed with a first reagent, it is then mixed with the reagent a containing at least two kinds of receptor microspheres with different particle sizes.
  • the first reagent in the present invention does not specifically refer to a certain type of reagent.
  • the first reagent is a reagent added to ensure the smooth or optimized performance of certain detection methods based on specific reactions.
  • the first reagent includes, but is not limited to, a biotinylated antigen or antibody.
  • the detection method of the specific reaction is a sandwich method.
  • the immune complex mode is: donor microspheres-streptavidin-biotin-antibody 1-antigen-antibody 2-acceptor microspheres.
  • the first reagent is a biotinylated antigen or antibody; Donor microspheres are coupled with a streptavidin donor microspheres, and recipient microspheres are coupled with an antigen or an antibody.
  • step S1 the test sample is first diluted with a diluent, and then mixed with the first reagent. After that, it is mixed with the donor microsphere reagent.
  • the method analyzes and determines whether the test sample contains the test sample by detecting the intensity of the chemiluminescence signal generated by the reaction between three kinds of acceptor microspheres with different particle sizes and reactive oxygen species in the test sample.
  • the concentration of the target molecule and / or the target molecule to be measured is a parameter that determines whether the test sample contains the test sample.
  • the detection wavelength of the chemiluminescence signal is 520-620 nm, preferably 610-620 nm, and more preferably 615 nm.
  • laser irradiation is performed with red excitation light at 600 to 700 nm; laser irradiation with red excitation light at 640-680 nm is preferred; laser irradiation with red excitation light at 660 nm is more preferred.
  • the acceptor microsphere includes a luminescent composition and a matrix, and the luminescent composition is filled in the matrix and / or coated on the surface of the matrix.
  • the luminescent composition is capable of reacting with active oxygen to generate a detectable chemiluminescent signal, which comprises a chemiluminescent compound and a metal chelate.
  • the chemiluminescent compound is selected from olefin compounds, and the olefin compounds are compounds capable of reacting with active oxygen (such as singlet oxygen).
  • active oxygen such as singlet oxygen.
  • suitable electron-rich olefinic compounds are listed in US Patent No. 5,709,994, which is incorporated herein by reference.
  • the olefin compound is selected from the group consisting of dimethylthiophene, dibutanedione compound, dioxane, enol ether, enamine, 9-alkylene xanthene , 9-alkylene-N-9,10 dihydroacridine, aryl etherene, arylimidazole, and gloss derivatives and their derivatives, more preferably selected from dimethylthiophene and its derivatives.
  • the chemiluminescent compounds include complexes (metal chelates) of a metal and one or more chelating agents.
  • the metal of the metal chelate is a rare earth metal or a Group VIII metal, preferably selected from the group consisting of rhenium, osmium, osmium, osmium, osmium, and ruthenium, and more preferably selected from osmium.
  • the metal chelate comprises a chelating agent selected from the group consisting of 4 '-(10-methyl-9-anthracenyl) -2,2': 6'2 " -Bitripyridine-6,6 "-dimethylamine] tetraacetic acid (MTTA), 2- (1 ', 1', 2 ', 2', 3 ', 3'-heptafluoro-4', 6'- Hexamethylene dione-6'-yl) -naphthalene (NHA), 4,4'-bis (2 ", 3", 3 "-heptafluoro-4", 6 "-hexanedione-6” -yl)- O-terphenyl (BHHT), 4,4'-bis (1 ”, 1”, 1 ”, 2”, 2 ”, 3”, 3 ”-heptafluoro-4”, 6 ”-hexanedione-6 "-Yl) -chlorosulfo-o-terphenyl
  • the luminescent compound is a derivative of dimethylthiophene, and the metal chelate is a europium chelate.
  • the matrix is selected from the group consisting of tapes, sheets, rods, tubes, wells, microtiter plates, beads, particles and microspheres; preferably beads and microspheres.
  • the matrix is magnetic or non-magnetic particles.
  • the materials of the substrates of the receptor microspheres with different particle sizes are the same or different.
  • the matrix material is selected from the group consisting of natural, synthetic, or modified naturally occurring polymers, including but not limited to: agarose, cellulose, nitrocellulose, cellulose acetate, Polyvinyl chloride, polystyrene, polyethylene, polypropylene, poly (4-methylbutene), polyacrylamide, polymethacrylate, polyethylene terephthalate, nylon, polybutyrate Or polyacrylate.
  • natural, synthetic, or modified naturally occurring polymers including but not limited to: agarose, cellulose, nitrocellulose, cellulose acetate, Polyvinyl chloride, polystyrene, polyethylene, polypropylene, poly (4-methylbutene), polyacrylamide, polymethacrylate, polyethylene terephthalate, nylon, polybutyrate Or polyacrylate.
  • the matrix is an aldehyde-based latex microsphere; preferably an aldehyde-based polystyrene latex microsphere.
  • a biologically active substance is directly connected to the surface of the matrix, and the biologically active substance can specifically bind to a target molecule to be detected.
  • the surface of the substrate is coated with a coating layer, and the surface of the coating layer is connected with a biologically active substance, which can specifically bind to a target molecule to be measured;
  • a biologically active substance which can specifically bind to a target molecule to be measured
  • the ions of the biologically active substance-target molecule binding partner include antigen-antibody, hormone-hormone receptor, nucleic acid duplex, IgG-protein A, and polynucleotide pair such as DNA- DNA, DNA-RNA, etc.
  • the biologically active substance is an antigen and / or an antibody;
  • the antigen refers to a substance having immunogenicity;
  • the antibody refers to an immunity produced by the body that can recognize a specific foreign object globulin.
  • the coating in the coating layer is selected from a polysaccharide, a polymer, or a biomacromolecule, and is preferably a polysaccharide.
  • the surface of the matrix is coated with a coating of at least two continuous polysaccharide layers, wherein the first polysaccharide layer is spontaneously associated with the second polysaccharide layer.
  • each of the continuous polysaccharide layers is spontaneously associated with each of the previous polysaccharide layers.
  • the polysaccharide has a side group functional group, and the functional group of the continuous polysaccharide layer has an opposite charge to the functional group of the previous polysaccharide layer.
  • the polysaccharide has a pendant functional group, and the continuous layer of the polysaccharide is reacted with the functional group of the continuous layer and the functional group of the previous layer by The former polysaccharide layer is covalently linked.
  • the functional group of the continuous polysaccharide layer alternates between an amine functional group and an amine-reactive functional group.
  • the amine-reactive functional group is an aldehyde group or a carboxyl group.
  • the first polysaccharide layer is spontaneously associated with the carrier.
  • the outermost polysaccharide layer of the coating has at least one pendant functional group.
  • the side functional group of the outermost polysaccharide layer of the coating is selected from at least one of an aldehyde group, a carboxyl group, a thiol group, an amino group, a hydroxyl group, and a maleamine group; From aldehyde and / or carboxyl.
  • the side group functional group of the outermost polysaccharide layer of the coating is directly or indirectly connected to the bioactive substance.
  • the polysaccharide is selected from a carbohydrate containing three or more unmodified or modified monosaccharide units; preferably selected from dextran, starch, glycogen, inulin, fruit Glycans, mannans, agaroses, galactans, carboxydextran and aminodextran; more preferably selected from dextran, starch, glycogen and polyribose.
  • the matrix diameters of the receptor microspheres with different particle diameters are the same.
  • the size of the matrix of the acceptor microspheres with different particle sizes is different.
  • the active oxygen is singlet oxygen.
  • the composition and chemical structure of the acceptor microspheres with different particle diameters may be the same or different.
  • the respective light-emitting compositions and / or substrates of the acceptor microspheres with different particle diameters may be the same or different, as long as they are capable of reacting with active oxygen to generate a detectable chemiluminescence signal.
  • a second aspect of the present invention relates to a chemiluminescence analyzer using the method according to the first aspect of the present invention to detect the presence and / or concentration of a target molecule in a sample to be tested.
  • the chemiluminescence analyzer includes at least the following parts:
  • An incubation module which is used to provide a suitable temperature environment for a chemiluminescence reaction after mixing a sample to be measured and at least two kinds of acceptor microspheres with different particle diameters;
  • a processor which determines whether a target molecule to be tested exists in the sample to be tested and / or a concentration of the target molecule to be tested in the sample to be tested according to the situation of the chemiluminescence signal detected by the detection module.
  • a third aspect of the present invention relates to a method according to the first aspect of the present invention and / or a chemiluminescence analyzer according to the second aspect of the present invention for detecting myocardial injury markers including cTnI and / or including Application of procalcin in inflammation markers.
  • the emulsion after the reaction is completed is cooled to room temperature and filtered with a suitable filter cloth.
  • the obtained emulsion was washed with deionized water by centrifugal sedimentation until the conductivity of the supernatant of the initial centrifugation was close to that of deionized water, and then diluted with water and stored in the form of an emulsion.
  • step 3 Slowly add the complex solution in step 1 to the three-necked flask in step 2, and stop the stirring after reacting at 70 ° C for 2 hours, and naturally cool.
  • Receptor microspheres with aldehyde groups having particle sizes of 50 nm, 80 nm, 110 nm, 170 nm, 250 nm, 300 nm, 350 nm, and 400 nm were prepared by the same method.
  • Example 2 Determination of sensitivity and upper limit of detection by chemiluminescence analysis method using acceptor microspheres of different particle sizes
  • the sensitivity point is defined as when the signal of concentration 2C0 is higher than the signal of twice the concentration C0, that is, RLU (2C0)> 2RLU (C0), the corresponding detection reagent sensitivity is C0.
  • the upper limit of detection is defined as the corresponding concentration calculated by substituting the detection signal with a concentration of 1000 ng / ml into the curve of the concentration and signal.
  • cTnI antigen Dilute cTnI antigen to 5 pg / ml, 10 pg / ml, 20 pg / ml, 30 pg / ml, 40 pg / ml, 50 pg / ml, 100 pg / ml, 1000 pg / ml, 5000 pg / ml, 10000 pg / ml, 50000 pg / ml
  • cTnI monoclonal antibody 1 coated with different particle diameters 50nm, 80nm, 110nm, 140nm, 170nm, 200nm, 250nm, 300nm, 350nm, 400nm
  • Example 1 Dilute cTnI antigen to 5 pg / ml, 10 pg / ml, 20 pg / ml, 30 pg / ml, 40 pg / ml, 50
  • the recipient microspheres were diluted to 100 ug / ml, and then the same concentration of biotinylated cTnI mAb 2 (diluted to 2 ug / ml) and universal solution (donor microsphere solution) were used to detect the above-mentioned series of cTnI antigens.
  • the detection sensitivity and The upper detection limit is shown in Table 1.
  • the spheres were then tested with the same biotin-labeled PCT mAb 2 (diluted to 2ug / ml) and universal solution (donor microsphere solution) for the above-mentioned concentration series of PCT antigens.
  • the detection sensitivity and upper limit of detection are shown in Table 1.
  • Detection result of cTnI project The upper limit of detection of 50nm and 80nm receptor microspheres is very high, but the sensitivity is poor, while the 300nm receptor microsphere has the best sensitivity, but the lower detection limit. 50nm and 80nm acceptor microspheres were mixed with 300nm acceptor microspheres to form a composition of acceptor microspheres with different particle sizes. The sensitivity and upper limit of detection using the corresponding composition chemiluminescence analysis method were tested. The results are shown in the table. 2 shown.
  • a chemiluminescence analysis method using a composition formed by combining a small particle size acceptor microsphere and a large particle size acceptor microsphere has high sensitivity and a high detection limit (wide detection range). Shows the advantages of large particle size receptor microspheres and small particle size receptor microspheres. Compared with single particle size receptor microspheres, the performance of microsphere composition containing more than two particle sizes is greatly improved. .
  • the aldehyde group content of the latex microspheres was determined by conductometric titration to be 280 nmol / mg.
  • step 2 2) Prepare a 100 ml three-necked flask, add 10 ml of 95% ethanol, 10 ml of water, and 10 ml of the aldehyde-based polystyrene latex microspheres obtained in step 1.1, magnetically stir, and warm the water bath to 70 ° C;
  • step 1) Slowly add the complex solution in step 1) to the three-necked flask in step 2), stop stirring after reacting at 70 ° C for 2 hours, and naturally cool;
  • the paired antibody I was dialyzed to 50 mM CB buffer with a pH value of 10, and the concentration was measured to be 1 mg / ml.
  • the preparation method is the same as the preparation process of the acceptor microspheres with an average particle diameter of about 250nm in the above (1).
  • the Nicomp distribution is unimodal (as shown in Figure 6).
  • the preparation method is the same as the preparation process of the acceptor microspheres with an average particle diameter of about 250nm in the above (1).
  • Example 4 Determination of sensitivity and upper limit of detection by chemiluminescence analysis method using acceptor microspheres of different particle sizes
  • the sensitivity point is defined as when the signal of concentration Cx is higher than the signal of double concentration C0, that is, RLU (Cx)> 2RLU (C0), then the corresponding detection reagent sensitivity is Cx.
  • the upper limit of detection is defined as the upper limit of the range determined using the methods in the documents of the National Committee for Clinical Laboratory Standards (NCCLS) Evaluation Protocol (EP) Series 6.

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plasma & Fusion (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

化学发光分析技术领域的一种化学发光分析方法，其通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。既有超高的灵敏度，又有很宽的检测量程。另外，由于小粒径发光微球的反应速度快，因此进行检测时还能缩短检测时间，反应速度得到提升。

Description

一种化学发光分析方法及其应用
相关申请的交叉引用
本申请要求享有于2018年8月13日提交的名称为“一种化学发光分析方法及其应用”的中国专利申请CN201810915152.2的优先权，该申请的全部内容通过引用并入本文中。
技术领域
本发明属于化学发光分析技术领域，具体涉及一种化学发光分析方法及其应用。
背景技术
化学发光分析法是一种利用化学发光物质发射的光波进行检测的方法。化学发光物质作为标记应用于核酸检测与免疫检测中。例如，可通过多种途径将特异结合对中的某一分子与发光物质结合形成发光微球组合物。该微球组合物可与样品中被检测物(特异结合对中的另一分子)反应，分配于固相与液相中，且分配比例与检测物的量相关。通过测定固相或液相中发光量，即可得出样品中检测物的相应浓度。
目前随着检测行业的进步，对超敏试剂的需求越来越多，不但对灵敏度要求极高，而且线性范围又要求非常宽，现有的化学发光分析方法很难满足上述检测条件。
因此，亟需开发一种既能满足灵敏度要求、又能满足线性范围要求的化学发光分析方法。
发明内容
本发明所要解决的技术问题是针对现有技术的不足，提供一种化学发光分析方法，该方法既有超高的灵敏度，又有很宽的检测量程。另外，该方法还能够缩短检测时间。
为此，本发明提供了一种化学发光分析方法，其通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述方法通过检测待测样品中的两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述两种不同粒径的受体微球的粒径差值不低于100nm；优选不低于150nm；更优选不低于200nm。
在本发明的另一些实施方式中，所述两种不同粒径的受体微球的粒径比选自1:(1.1-10)；优选选自1:(2-8)；更优选选自1:(3-6)。
在本发明的一些实施方式中，所述受体微球的使用浓度为1ug/mL-1000ug/mL；优选为10ug/mL-500ug/mL；更优选为10ug/mL-250ug/mL。
在本发明的一些实施方式中，所述待测样品中还包括供体微球，所述供体微球能够在激发状态下生成活性氧。
在本发明的另一些实施方式中，所述方法为均相化学发光分析方法。
在本发明的一些优选的实施方式中，所述方法包括以下步骤：
S1，将待测样本与包含至少两种不同粒径的受体微球的试剂a混合后，再与包含供体微球的试剂b混合，从而得到待测样品；
S2，利用能量或活性化学物与步骤S1中得到的待测样品接触，激发供体产生活性氧；
S3，通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述待测样本利用稀释液稀释后再进行反应。
在本发明的一些实施方式中，所述方法通过检测待测样品中的三种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述化学发光信号的检测波长为520～620nm。
在本发明的另一些实施方式中，采用600～700nm的红色激发光进行激光照射。
在本发明的一些实施方式中，所述受体微球包括发光组合物和基质，所述发光组合物填充于基质中和/或包被于基质表面。
在本发明的一些优选的实施方式中，所述发光组合物能够与活性氧反应产生可检测的化学发光信号，其包含化学发光化合物和金属螯合物。
在本发明的一些具体实施方式中，所述化学发光化合物选自烯烃化合物，优选选自二甲基噻吩、双丁二酮化合物、二氧杂环己烯、烯醇醚、烯胺、9-亚烷基苍耳烷、9-亚烷基-N-9,10二氢化吖啶、芳基乙醚烯、芳基咪唑和光泽精以及它们的衍生物，更优选选自二甲基噻吩及其衍生物。
在本发明的另一些具体实施方式中，所述金属螯合物的金属是稀土金属或VIII族金属，优选选自铕、铽、镝、钐、锇和钌，更优选选自铕。
在本发明的一些优选的实施方式中，所述金属螯合物包含选自下列的螯合剂：MTTA、NHA、BHHT、BHHCT、DPP、TTA、NPPTA、NTA、TOPO、TPPO、BFTA、2,2-二甲基-4-全氟丁酰-3-丁酮(fod)、2,2’-联吡啶(bpy)、联吡啶基羧酸、氮杂冠醚、氮杂穴状配体和三辛基氧化膦以及它们的衍生物。
在本发明的一些实施方式中，所述发光化合物是二甲基噻吩的衍生物，所述金属螯合物是铕螯合物。
在本发明的一些实施方式中，所述基质选自带、片、棒、管、孔、微滴定板、珠、粒子和微球；优选为珠和微球。
在本发明的另一些实施方式中，所述基质是磁性或非磁性粒子。
在本发明的一些实施方式中，所述不同粒径的受体微球的基质的材质相同或不同。
在本发明的一些具体实施方式中，所述基质材料选自天然的、合成或改性的天然存在的聚合物，其包括但不限于：琼脂糖、纤维素、硝化纤维素、醋酸纤维素、聚氯乙烯、聚苯乙烯、聚乙烯、聚丙烯、聚(4-甲基丁烯)、聚丙烯酰胺、聚甲基丙烯酸酯、聚对苯二甲酸乙二醇酯、尼龙、聚丁酸乙烯或聚丙烯酸酯。
在本发明的一些优选的实施方式中，所述基质为醛基化乳胶微球；优选为醛基化聚苯乙烯乳胶微球。
在本发明的一些实施方式中，所述基质的表面直接连接有生物活性物质，所述生物活性物质能够与待测目标分子特异性结合。
在本发明的另一些实施方式中，所述基质的表面包被包覆层，所述包覆层的表面连接有生物活性物质，所述生物活性物质能够与待测目标分子特异性结合。
在本发明的一些实施方式中，所述包覆层中的包覆物选自多糖、高分子聚合物或生物大分子，优选为多糖。
在本发明的另一些实施方式中，所述基质的表面包被至少两个连续多糖层的涂层，其中第一多糖层与第二多糖层自发关联。
在本发明的一些实施方式中，所述连续多糖层中的每一层自发地与前一多糖层中的每一层相关联。
在本发明的另一些实施方式中，所述多糖具有侧基官能团，所述连续多糖层的所述官能团与所述前一多糖层的所述官能团所带电荷相反。
在本发明的一些实施方式中，所述多糖具有侧基官能团，并且所述多糖的所述连续层通过所述连续层的所述官能团与所述前一层的所述官能团之间的反应与所述前一多糖层共价连接。
在本发明的另一些实施方式中，所述连续多糖层的所述官能团在胺官能团和胺反应性官能团之间交替。
在本发明的一些实施方式中，所述胺反应性官能团是醛基或羧基。
在本发明的另一些实施方式中，所述第一多糖层自发地与所述载体相关联。
在本发明的一些实施方式中，所述涂层的最外一层多糖层具有至少一个侧基官能团。
在本发明的另一些实施方式中，所述涂层的最外一层多糖层的侧基官能团选自醛基、羧基、巯基、氨基、羟基和马来胺基中的至少一种；优选选自醛基和/或羧基。
在本发明的一些实施方式中，所述涂层的最外一层多糖层的侧基官能团直接地或间接地与生物活性物质连接。
在本发明的另一些实施方式中，所述多糖选自含有三个或更多个未修饰或修饰的单糖单元的碳水化合物；优选选自葡聚糖、淀粉、糖原、菊粉、果聚糖、甘露聚糖、琼脂糖、半乳聚糖、羧基葡聚糖和氨基葡聚糖；更优选选自葡聚糖、淀粉、糖原和聚核糖。
在本发明的一些实施方式中，所述不同粒径的受体微球的基质粒径相同。
在本发明的另一些实施方式中，所述不同粒径的受体微球的基质粒径不同。
在本发明的一些实施方式中，所述活性氧为单线态氧。
本发明第二方面提供了一种利用如本发明第一方面所述的方法来检测待测样品中待测目标分子是否存在和/或待测目标分子的浓度的化学发光分析仪。
在本发明的一些实施方式中，所述化学发光分析仪至少包括如下部分：
孵育模块，其用于为待测样本和至少两种不同粒径的受体微球混合后发生化学发光反应提供合适的温度环境；
检测模块，其用于检测受体微球与活性氧反应产生的化学发光信号；
处理器，其根据检测模块检测到的化学发光信号的情况判断待测样本中是否存在待测目标分子和/或待测目标分子在待测样本中的浓度。
本发明第三方面提供了一种如本发明第一方面所述的方法和/或如本发明第二方面所述的化学发光分析仪在检测包括cTnI在内的心肌损伤标志物和/或包括降钙素原在内的炎症标志物中的应用。
本发明的有益效果为：本发明所述化学发光分析方法，通过在待测样本中加入包含至少两种不同粒径的受体微球(小粒径的受体微球和大粒径的受体微球)，由于小粒径的受体微球能拓宽检测量程、大粒径的受体微球能提高检测灵敏度，使得本发明所述方法的检测性能较现有技术得到大幅提升，既有超高的灵敏度，又有很宽的检测量程。另外，由于小粒径受体微球的反应速度快，因此采用本发明所述方法进行检测时还能缩短检测时间，反应速度得到提升。
附图说明
下面将结合附图对本发明作进一步说明。
图1为实施例3中制备的醛基聚苯乙烯乳胶微球的Gaussian分布曲线图。
图2为实施例3中制备的填埋有发光组合物的醛基聚苯乙烯乳胶微球的Gaussian分布曲线图。
图3为实施例3制备的包被葡聚糖的填埋有发光组合物的醛基聚苯乙烯乳胶微球的Gaussian分布图
图4为实施例3制备的平均粒径在250nm左右的受体微球的Gaussian分布图。
图5为实施例3制备的粒径在110nm左右的受体微球的Gaussian分布图。
图6为实施例3制备的粒径在110nm左右的受体微球的Nicomp分布图。
图7为实施例3制备的粒径在350nm左右的的受体微球的Gaussian分布图。
图8为实施例3制备的粒径在350nm左右的的受体微球的Nicomp分布图。
图9为实施例4中混合受体微球粒径分布的Gaussian分布图。
图10为实施例4中混合受体微球粒径分布的Nicomp分布图。
具体实施方式
为使本发明容易理解，下面将详细说明本发明。但在详细描述本发明前，应当理解本发明不限于描述的具体实施方式。还应当理解，本文中使用的术语仅为了描述具体实施方式，而并不表示限制性的。
在提供了数值范围的情况下，应当理解所述范围的上限和下限和所述规定范围中的任何其他规定或居间数值之间的每个居间数值均涵盖在本发明内。这些较小范围的上限和下限可以独立包括在较小的范围中，并且也涵盖在本发明内，服从规定范围中任何明确排除的限度。在规定的范围包含一个或两个限度的情况下，排除那些包括的限度之任一或两者的范围也包含在本发明中。
除非另有定义，本文使用的所有术语与本发明所属领域的普通技术人员的通常理解具有相同的意义。虽然与本文中描述的方法和材料类似或等同的任何方法和材料也可在本发明的实施或测试中使用，但是现在描述了优选的方法和材料。
Ⅰ.术语
本发明所述用语“活性氧”是指机体内或者自然环境中由氧组成，含氧并且性质活泼的物质的总称，主要为一种激发态的氧分子，包括氧的一电子还原产物超氧阴离子(O 2·-)、二电子还原产物过氧化氢(H 2O 2)、三电子还原产物羟基自由基(·OH)以及一氧化氮和单线态氧(1O 2)等。
本发明中，所述用语“受体微球”是指能够与活性氧反应产生可检测的化学发光信号的纳米微球，其也可以称为受氧微球或发光微球。优选地，所述受体微球可以是通过功能基团填充于基质中形成填充有发光组合物的高分子微粒，所述发光组合物包含有能够与活性氧发生反应的化学发光化合物。在本发明的一些具体实施例中，所述化学发光化合物，其经历与活性氧的化学反应以形成不稳定的亚稳态中间体，所述亚稳态中间体可以分解，同时或随后发光。这些物质的典型 例子包括但不限于：烯醇醚、烯胺、9-烷叉黄原胶、9-烷叉-N-烷基吖啶满、芳基乙醚烯、双环氧乙烯、二甲基噻吩、芳基咪唑或光泽精。
本发明中，所述“化学发光化合物”即一种被称作为标记物的化合物，可进行化学反应以便引起发光，比如通过被转化为在电子激发态下形成的另一种化合物。激发态可以是单线态或是三重激发态。激发态可弛豫到基态直接发光，或者是通过将激发能量传递到发射能量受体，从而自身恢复到基态。在此过程中，能量受体微球将被跃迁为激发态而发光。
化学发光化合物可以结合到特异性结合伴侣成员上，该特异性结合伴侣成员能够直接或间接地与待测目标分子或测试成分结合，该测试成分的浓度受存在的待测目标分子的影响。用于“能够直接或间接地结合”是指指定的实体物能够特异地结合到实体物上(直接地)，或者指定的实体物能够特异性地结合至特异性结合配对成员、或具有两个或更多能够结合其他实体物的特异性结合伴侣的复合物上(间接地)。
本发明所述“特异性结合配对成员”选自(1)小分子和对于所述小分子的结合配偶体，以及(2)大分子和对于所述大分子的结合配偶体
在本发明中，所述活性氧可以由“供体微球”提供，所述供体微球是能够在激发状态下生成活性氧的纳米微球。优选地，所述供体微球可以是通过功能基团被包被在基体上形成填充有感光化合物的高分子微粒，在光激发下能够产生单线态氧，此时感光微球也可以称为供氧微球或感光微球。所述供体微球表面可以有亲水性的醛基葡聚糖，内部填充有光敏剂。所述光敏剂可以是本领域已知的光敏剂，优选相对光稳定且不与单线态氧有效反应的化合物，其非限定性的例子包括亚甲基蓝、玫瑰红、卟啉、和酞菁等化合物，以及这些化合物的具有1-50个原子取代基的衍生物，所述取代基用于使得这些化合物更具有亲脂性或更具有亲水性、和/或作为连接至特异性结合配对成员的连接基团。所述供体微球还可以填充其他敏化剂，其非限定性的例子是某些化合物，它们催化过氧化氢转化为单线态氧和水。其他一些供体的例子包括：1,4-二羧基乙基-1,4-萘内过氧化物、9,10-二苯基蒽-9,10-内过氧化物等，加热这些化合物或者这些化合物直接吸收光会释放活性氧，例如单线态氧。
本发明所述的“基质”其可以是任何尺寸的，其可以是有机的或是无机的，其可以是可膨胀或不可膨胀的，其可以是多孔的或非多孔的，其具有任何密度， 但优选具有和水接近的密度，优选能漂浮于水中，且由透明、部分透明或不透明的材料构成。所述基质可以有或没有电荷，当带有电荷时，优选是负电荷。所述基质可以是固体(如聚合物、金属、玻璃、有机和无机物诸如矿物、盐和硅藻)、小油滴(如碳氢化合物、碳氟化合物、硅质流体)、囊泡(如合成的诸如磷脂、或天然的诸如细胞、及细胞器官)。基质可以是乳胶颗粒或是含有有机或无机聚合物的其他颗粒、脂双层如脂质体、磷脂囊泡、小油滴、硅颗粒、金属溶胶、细胞和微晶染料。基质通常具有多功能性，或者能够通过特异或非特异的共价或非共价相互作用而结合到供体或受体上。有许多官能团是可用的或者将其合并进来。典型的官能团包括羧酸、乙醛、氨基、氰基、乙烯基、羟基、巯基等。适用于本发明的基质的一个非限制性的例子是醛基聚苯乙烯乳胶微球。
可以选择光敏剂和/或化学发光化合物溶解在、或非共价地结合到颗粒的表面。在这种情况下，这些化合物优选是疏水性的，以降低它们从颗粒解离下来的能力，从而使两种化合物都能和相同的颗粒结合。
本发明所述用语“粒径”是指发光微球的平均粒径，它是用常规粒径仪测定的。本发明所述“受体微球”至少包括基质、发光组合物以及生物活性分子，优选还包括包覆层；所述发光组合物可以填充于基质中和/或包被于基质表面。当所述受体微球不包括包覆层时，所述生物活性物质直接连接于基质表面。当所述受体微球包括包覆层时，所述包覆层包被于基质表面，且所述包覆层的最外层连接生物活性活性物质。
值得注意的是，本发明所述“受体微球的平均粒径”指的是连接和/或包覆上相应的物质后的受体微球的平均粒径。不同粒径的受体微球中的基质的粒径可以相同也可以不同，只要最终形成的受体微球的粒径不同即可，本发明最优选的技术方案是所述不同粒径的受体微球中的基质的粒径也不相同。
本发明所述用语“待测样本”是指检测待测的含有或疑似含有待测目标分子的一种混合物。可以被用在本发明公开的待测样本包括体液，如血液(可以是在收集的血液样品中通常看到的抗凝血)、血浆、血清、尿、精液、唾液、细胞培养物、组织提取物等。其他类型的待测样本包括溶剂、海水、工业水样、食品样品、环境样本诸如土或水、植物材料、真核细胞、细菌、质粒、病毒、真菌、及来自于原核的细胞。待测样本可以在使用前根据需要利用稀释液进行稀释。例如， 为了避免HOOK效应，可以在上机检测前使用稀释液对待测样本进行稀释后再在检测仪器上进行检测。
本发明所述用语“待测目标分子”是指检测时待检测样本中的物质。与待测目标分子具有特异性结合亲合力的一种或多种物质会被用于检测该目标分子。待测目标分子可以是蛋白、肽、抗体或可以使其与抗体结合的半抗原。待测目标分子可以是与互补核酸或寡聚核苷酸结合的核酸或寡聚核苷酸。待测目标分子可以是可形成特异性结合配对成员的任何其他物质。其他典型的待测目标分子的例子包括：药物，诸如类固醇、激素、蛋白、糖蛋白、粘蛋白、核蛋白、磷蛋白、滥用的药物、维生素、抗细菌药、抗真菌药、抗病毒药、嘌呤、抗肿瘤试剂、安非他命、杂氮化合物、核酸和前列腺素，以及任何这些药物的代谢物；杀虫剂及其代谢物；以及受体。分析物也包括细胞、病毒、细菌和真菌。
本发明所述用语“待测样品”是指上机检测分析前的含有待测样本、本发明所述受体微球以及供体微球等多组分的待测混合液体。
本发明所述用语“抗体”以最广含义使用，包括任何同种型的抗体，保留对抗原的特异性结合的抗体片段，包括但不限于Fab、Fv、scFv、和Fd片段、嵌合抗体、人源化抗体、单链抗体、双特异性抗体、和包含抗体的抗原结合部分和非抗体蛋白的融合蛋白。在任何需要的情况下，抗体可以进一步与其它部分，诸如特异性结合配对成员，例如生物素或链霉亲和素(生物素-链霉亲和素特异性结合配对成员中的一员)等缀合。
本发明所述用语“抗原”是指能够刺激机体产生免疫应答，并能与免疫应答产物抗体和致敏淋巴细胞在体内外结合，发生免疫效应的物质。
本发明所述用语“结合”指由于例如共价、静电、疏水、离子和/或氢键等相互作用，包括但不限于如盐桥和水桥等相互作用引起的两个分子间的直接联合。
本发明所述用语“特异性结合”，是指两种物质之间的相互辨别和选择性结合反应，从立体结构角度上说就是相应的反应物之间构象的对应性。在本发明公开的技术思想下，特异性结合反应的检测方法包括但不限于：双抗体夹心法、竞争法、中和竞争法、间接法或捕获法。
本发明所述用语“均相”所对应的英文定义为“homogeneous”，其是指无须对结合的抗原抗体复合物和剩余的游离抗原或抗体进行分离即可进行检测。
本发明所述“粒径分布变异系数C.V值”是指在纳米粒度仪的检测结果中，粒径在Gaussian分布中的变异系数。变异系数的计算公式为：C.V值＝(标准偏差SD/平均值Mean)×100％。
本发明所述用语“Nicomp分布”是指美国PSS纳米粒度仪NICOMP中的一种算法分布。相对于Gaussian单峰算法，Nicomp多峰算法对于多组分、粒径分布不均匀液态分散体系的分析以及胶体体系的稳定性分析具有独特优势。
Ⅱ.实施方式
下面将更详细地说明本发明。
本发明第一方面涉及一种化学发光分析方法，其通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述方法通过检测待测样品中的两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述两种不同粒径的受体微球的粒径差值不低于100nm；优选不低于150nm；更优选不低于200nm。在本发明的一些具体实施例中，所述两种不同粒径的受体微球的粒径的差值不低于100nm、130nm、150nm、170nm、190nm、200nm、220nm、240nm或250nm。
在本发明的另一些实施方式中，所述两种不同粒径的受体微球的粒径比选自1:(1.1-10)；优选选自1:(2-8)；更优选选自1:(3-6)。在本发明的一些具体实施例中，所述两种不同粒径的受体微球的的粒径比选自1:1.5、1:2、1:2.7、1:3、1:3.2、1:3.75、1:4、1:5或1:6。
在本发明的一些优选的实施方式中，其中一种受体微球的粒径选自50nm-300nm，而另一种受体微球的粒径选自200nm-400nm。例如，其中一种受体微球的粒径选自50nm、80nm、110nm、140nm、170nm、200nm或300nm，而另一种受体微球的粒径选自200nm、250nm、300nm、350nm或400nm。
在本发明的进一步优选的实施方式中，其中一种受体微球的粒径选自50nm-200nm，而另一种受体微球的粒径选自200nm-350nm。
在本发明的更进一步的实施方式中，其中一种受体微球的粒径选自80nm-150nm，而另一种受体微球的粒径选自220nm-350nm。本发明中，所述受体微球粒径的大小应能产生均匀稳定的乳胶溶液，一般能达到这个要求的受体微球的粒径应该在纳米范围内。因此大粒径受体微球的粒径上限是能生成稳定的乳胶溶液，一般选择300nm左右为宜。同时，受体微球的包被和清洗要能够在现有的技术条件下进行从而满足试剂的生产。
本发明所述方法通过控制所使用的微球组合物中受体微球的粒径，进而控制每个受体微球表面生物活性物质(如，抗体/抗原)的量(小粒径微球比表面积大，单位质量微球表面报告分子的量多，大粒径微球比表面积小，单位质量微球表面报告分子的量少)，从而提高检测的灵敏度和拓宽检测量程。另外小粒径受体微球由于直径较小，使得供体微球产生的单线氧的活化效率提高，从而也能提高受体微球微球的发光效率。
在本发明的一些实施方式中，所述受体微球的使用浓度为1ug/mL-1000ug/mL；优选为10ug/mL-500ug/mL，更优选为50ug/mL-250ug/mL。本发明中，所述受体微球的使用浓度由不同待测目标分子在血液中的浓度及待测目标分子的特性所决定。
在本发明的一些实施方式中，所述待测样品中还包括供体微球，所述供体微球能够在激发状态下生成活性氧。
在本发明的另一些实施方式中，所述方法为均相化学发光分析方法。
在本发明的一些优选的实施方式中，所述方法包括以下步骤：
S1，将待测样本与包含至少两种不同粒径的受体微球的试剂a混合后，再与包含供体微球的试剂b混合，从而得到待测样品；
S2，利用能量或活性化学物与步骤S1中得到的待测样品接触，激发供体产生活性氧；
S3，通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些具体实施方式中，所述受体微球在试剂a中的粒径分布变异系数C.V值可以为5％、6％、7％、8％、9％、10％、11％、12％、13％、14％、15％、16％、17％、18％、19％、20％、25％、30％、35％或40％等。
值得注意的是，本发明所述的受体微球粒径分布变异系数C.V值指的是受体微球包被上所需的物质后的粒径分布变异系数C.V值。
在本发明的一些优选的实施方式中，在步骤S1中，先将所述待测样本与第一试剂混合后，再与所述包含至少两种不同粒径的受体微球的试剂a混合。需要说明的是，本发明中所述的第一试剂，不特指某一类试剂，所述第一试剂是为了保证某些基于特异性反应的检测方法的顺利或优化进行而添加的试剂，所述第一试剂包括但不限于：生物素化的抗原或抗体。
在本发明的一些优选实施方式中，特异性反应的检测方法为夹心法。例如，免疫复合物模式为：供体微球-链霉亲和素-生物素-抗体1-抗原-抗体2-受体微球，此时，第一试剂为生物素化的抗原或抗体；供体微球上偶联有链霉亲和素的供体微球，受体微球上偶联有抗原或抗体。
为进一步提高最终检测结果的准确性和待测样本的稳定性，在本发明的一些优选实施方式中，在步骤S1中，先将所述待测样本利用稀释液稀释，然后与第一试剂混合后，再与所述供体微球试剂混合。
在本发明的一些实施方式中，所述方法通过检测待测样品中的三种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
在本发明的一些实施方式中，所述化学发光信号的检测波长为520～620nm，优选为610-620nm，更优选为615nm。
在本发明的另一些实施方式中，采用600～700nm的红色激发光进行激光照射；优选采用640-680nm的红色激发光进行激光照射；更优选采用660nm的红色激发光进行激光照射。
在本发明的一些实施方式中，所述受体微球包括发光组合物和基质，所述发光组合物填充于基质中和/或包被于基质表面。
在本发明的一些优选的实施方式中，所述发光组合物能够与活性氧反应产生可检测的化学发光信号，其包含化学发光化合物和金属螯合物。
在本发明的一些具体实施方式中，所述化学发光化合物选自烯烃化合物，烯烃化合物是能够与活性氧(如单线态氧)反应的化合物。合适的富含电子的烯化合物的例子在美国专利号5,709,994中列出，相关的内容通过引用并入本文。在本发明的一些优选的实施方式中，所述烯烃化合物选自二甲基噻吩、双丁二酮化合物、二氧杂环己烯、烯醇醚、烯胺、9-亚烷基苍耳烷、9-亚烷基-N-9,10二氢化 吖啶、芳基乙醚烯、芳基咪唑和光泽精以及它们的衍生物，更优选选自二甲基噻吩及其衍生物。
除了烯烃化合物外，所述化学发光化合物还包括金属和一个或多个螯合剂的复合物(金属螯合物)。在本发明的一些具体实施方式中，所述金属螯合物的金属是稀土金属或VIII族金属，优选选自铕、铽、镝、钐、锇和钌，更优选选自铕。
在本发明的一些优选的具体实施方式中，所述金属螯合物包含选自下列的螯合剂：4’-(10-甲基-9-蒽基)-2,2’:6’2”-联三吡啶-6,6”-二甲胺]四乙酸(MTTA)、2-(1’,1’,2’,2’,3’,3’-七氟-4’,6’-己二酮-6’-基)-萘(NHA)、4,4’-二(2”,3”,3”-七氟-4”,6”-己二酮-6”-基)-邻-三联苯(BHHT)、4,4’-二(1”,1”,1”,2”,2”,3”,3”-七氟-4”,6”-己二酮-6”-基)-氯代磺基-邻-三联苯(BHHCT)、4,7-联苯-1,10-菲咯啉(DPP)、1,1,1-三氟丙酮(TTA)、3-萘酰-1,1,1-三氟丙酮(NPPTA)、萘基三氟丁二酮(NTA)、三辛基氧化膦(TOPO)、三苯基氧化膦(TPPO)、3-苯甲酰-1,1,1-三氟丙酮(BFTA)、2,2-二甲基-4-全氟丁酰-3-丁酮(fod)、2,2’-联吡啶(bpy)、联吡啶基羧酸、氮杂冠醚、氮杂穴状配体和三辛基氧化膦以及它们的衍生物。
在本发明的一些实施方式中，所述发光化合物是二甲基噻吩的衍生物，所述金属螯合物是铕螯合物。
在本发明的一些实施方式中，所述基质选自带、片、棒、管、孔、微滴定板、珠、粒子和微球；优选为珠和微球。
在本发明的另一些实施方式中，所述基质是磁性或非磁性粒子。
在本发明的一些实施方式中，所述不同粒径的受体微球的基质的材质相同或不同。
在本发明的一些具体实施方式中，所述基质材料选自天然的、合成或改性的天然存在的聚合物，其包括但不限于：琼脂糖、纤维素、硝化纤维素、醋酸纤维素、聚氯乙烯、聚苯乙烯、聚乙烯、聚丙烯、聚(4-甲基丁烯)、聚丙烯酰胺、聚甲基丙烯酸酯、聚对苯二甲酸乙二醇酯、尼龙、聚丁酸乙烯或聚丙烯酸酯。
在本发明的一些优选的实施方式中，所述基质为醛基化乳胶微球；优选为醛基化聚苯乙烯乳胶微球。
在本发明的一些实施方式中，所述基质的表面直接连接有生物活性物质，所述生物活性物质能够与待测目标分子特异性结合。
在本发明的另一些实施方式中，所述基质的表面包被包覆层，所述包覆层的表面连接有生物活性物质，所述生物活性物质能够与待测目标分子特异性结合；举例说明但非限定地，所述的生物活性物质-待测目标分子结合配偶体的离子包括抗原-抗体、激素-激素受体、核酸双链体、IgG-蛋白质A、多核苷酸对例如DNA-DNA、DNA-RNA等。
在本发明的一些优选的实施方式中，所述生物活性物质为抗原和/或抗体；所述抗原是指具有免疫原性的物质；所述抗体是指机体产生的能识别特定外来物的免疫球蛋白。
在本发明的一些实施方式中，所述包覆层中的包覆物选自多糖、高分子聚合物或生物大分子，优选为多糖。
在本发明的另一些实施方式中，所述基质的表面包被至少两个连续多糖层的涂层，其中第一多糖层与第二多糖层自发关联。
在本发明的一些实施方式中，所述连续多糖层中的每一层自发地与前一多糖层中的每一层相关联。
在本发明的另一些实施方式中，所述多糖具有侧基官能团，所述连续多糖层的所述官能团与所述前一多糖层的所述官能团所带电荷相反。
在本发明的一些实施方式中，所述多糖具有侧基官能团，并且所述多糖的所述连续层通过所述连续层的所述官能团与所述前一层的所述官能团之间的反应与所述前一多糖层共价连接。
在本发明的另一些实施方式中，所述连续多糖层的所述官能团在胺官能团和胺反应性官能团之间交替。
在本发明的一些实施方式中，所述胺反应性官能团是醛基或羧基。
在本发明的另一些实施方式中，所述第一多糖层自发地与所述载体相关联。
在本发明的一些实施方式中，所述涂层的最外一层多糖层具有至少一个侧基官能团。
在本发明的另一些实施方式中，所述涂层的最外一层多糖层的侧基官能团选自醛基、羧基、巯基、氨基、羟基和马来胺基中的至少一种；优选选自醛基和/或羧基。
在本发明的一些实施方式中，所述涂层的最外一层多糖层的侧基官能团直接地或间接地与生物活性物质连接。
在本发明的另一些实施方式中，所述多糖选自含有三个或更多个未修饰或修饰的单糖单元的碳水化合物；优选选自葡聚糖、淀粉、糖原、菊粉、果聚糖、甘露聚糖、琼脂糖、半乳聚糖、羧基葡聚糖和氨基葡聚糖；更优选选自葡聚糖、淀粉、糖原和聚核糖。
在本发明的一些实施方式中，所述不同粒径的受体微球的基质粒径相同。
在本发明的另一些实施方式中，所述不同粒径的受体微球的基质粒径不同。
在本发明的一些优选的实施方式中，所述活性氧为单线态氧。
本发明中，所述不同粒径的受体微球的组成及化学结构，各自可以相同，也可以各不同。例如，不同粒径的受体微球各自的发光组合物和/或基质可以相同，亦可以不同，只要满足能够与活性氧反应产生可检测的化学发光信号即可。
本发明第二方面涉及一种利用如本发明第一方面所述的方法来检测待测样本中待测目标分子是否存在和/或待测目标分子的浓度的化学发光分析仪。
在本发明的一些实施方式中，所述化学发光分析仪至少包括如下部分：
孵育模块，其用于为待测样本和至少两种不同粒径的受体微球混合后发生化学发光反应提供合适的温度环境；
检测模块，其用于检测受体微球与活性氧反应产生的化学发光信号；
处理器，其根据检测模块检测到的化学发光信号的情况判断待测样本中是否存在待测目标分子和/或待测目标分子在待测样本中的浓度。
本发明第三方面涉及一种如本发明第一方面所述的方法和/或如本发明第二方面所述的化学发光分析仪在检测包括cTnI在内的心肌损伤标志物和/或包括降钙素原在内的炎症标志物中的应用。
Ⅲ.具体实施例
为使本发明更加容易理解，下面将结合实施例来进一步详细说明本发明，这些实施例仅起说明性作用，并不局限于本发明的应用范围。本发明中所使用的原料或组分若无特殊说明均可以通过商业途径或常规方法制得。
实施例1：不同粒径的受体微球的制备
(1)醛基聚苯乙烯乳胶微球的制备及表征过程
1.准备100ml的三口烧瓶，加入40mmol苯乙烯、5mmol丙烯醛、10ml水，搅拌10min后通N 2 30min。
2.称取0.11g过硫酸铵和0.2g氯化钠，溶于40ml水中配置成水溶液。将该水溶液加入到步骤1的反应体系中，继续通N 2 30min。
3.将反应体系升温至70℃，反应15小时。
4.将反应完成后的乳液冷却至室温，用合适的滤布过滤。得到的乳液用去离子水过次离心沉降清洗，直至离心初的上清液的电导率接近去离子水，然后用水稀释，以乳液形式保存。
5.由纳米粒度仪测得该乳胶微球粒径为190.4nm，CV＝5.1％；由电导滴定法测得该乳胶微球醛基含量为280nmol/mg。
(2)发光组合物的包被过程及表征过程
1.准备25ml的圆底烧瓶，加入0.1g二甲基噻吩衍生物和0.1g铕(Ⅲ)配合物(MTTA-EU 3+)，10ml 95％乙醇，磁力搅拌，水浴升温至70℃，获得配合物溶液。
2.准备100ml的三口烧瓶，加入10ml 95％乙醇、10ml水和10ml浓度为10％、粒径140nm的醛基聚苯乙烯乳胶微球，磁力搅拌，水浴升温至70℃。
3.将步骤1中的配合物溶液缓慢滴加至步骤2中的三口烧瓶中，70℃反应2小时后停止搅拌，自然冷却。
4.将上述乳液离心1小时，30000G，离心后弃去上清液，用50％乙醇重新悬浮。重复离心清洗三次后用PH值＝10的50mM CB缓冲液重新悬浮，使其终浓度为20mg/ml。
(3)抗体的偶联过程
1.将PCT抗体1透析至PH值＝10的50mM CB缓冲液，测得浓度为1mg/ml。
2.在2ml离心管中加入0.5ml不同粒径带有醛基的受体微球，0.5ml步骤1获得的配对抗体Ⅰ，混匀后加入100μl 10mg/ml NaBH 4溶液(50mM CB缓冲液)，2-8℃反应4小时。
3.反应完毕后加入0.5ml 100mg/ml BSA溶液(50mM CB缓冲液)，2-8℃反应2小时。
4.反应完毕后将离心45min，30000G，离心后弃去上清液，用50mM MES缓冲液重新悬浮。重复离心清洗四次，并稀释至终浓度为100μg/ml，获得偶联PCT抗体1的受体微球。
5.由纳米粒度仪测得该受体微球的粒径为210.4nm，CV＝5.1％。
用同样方法制得粒径为50nm、80nm、110nm、170nm、250nm、300nm、350nm、400nm的带有醛基的受体微球。
实施例2：采用不同粒径的受体微球的化学发光分析方法灵敏度和检测上限的测定
定义灵敏度点为当浓度2C0的信号高于两倍浓度C0的信号，即RLU(2C0)>2RLU(C0)，则对应的检测试剂灵敏度为C0。定义检测上限点为浓度1000ng/ml的检测信号代入浓度与信号的曲线反算出的对应浓度。
(1)将cTnI抗原稀释到5pg/ml、10pg/ml、20pg/ml、30pg/ml、40pg/ml、50pg/ml、100pg/ml、1000pg/ml、5000pg/ml、10000pg/ml、50000pg/ml、1000ng/ml的系列浓度，将采用与实施例1相同的方法制备不同粒径(50nm、80nm、110nm、140nm、170nm、200nm、250nm、300nm、350nm、400nm)包被cTnI单抗1的受体微球分别稀释到100ug/ml，然后与相同的生物素标记的cTnI单抗2(稀释到2ug/ml)和通用液(供体微球溶液)检测上述浓度系列cTnI抗原，检测灵敏度和检测上限如表1所示。
(2)将PCT抗原稀释到20pg/ml、30pg/ml、40pg/ml、60pg/ml、80pg/ml、160pg/ml、500pg/ml、1000pg/ml、5000pg/ml、20000pg/ml、100000pg/ml及2000ng/ml的系列浓度，将采用实施例1制备的不同粒径(50nm、80nm、110nm、140nm、170nm、200nm、250nm、300nm、350nm、400nm)包被PCT单抗1的受体微球，然后与相同的生物素标记的PCT单抗2(稀释到2ug/ml)和通用液(供体微球溶液)检测上述浓度系列PCT抗原，检测灵敏度和检测上限如表1所示。
表1
Figure PCTCN2019100341-appb-000001
Figure PCTCN2019100341-appb-000002
从表1可知，
(1)cTnI项目检测结果：在50nm、80nm的受体微球的检测上限很高，但是灵敏度较差，而300nm的受体微球有最佳的灵敏度，但是检测上限较低。将50nm和80nm的受体微球分别与300nm受体微球混合，形成不同粒径的受体微球的组合物，检测采用相应的组合物化学发光分析方法的灵敏度和检测上限，结果如表2所示。
(2)PCT项目检测结果：在110nm的受体微球的检测上限很高，但是灵敏度较差，而300nm、350nm的受体微球有最佳的灵敏度，但是检测上限较低。将110nm受体微球分别与300nm、350nm受体微球混合，形成不同粒径的受体微球的组合物，检测采用相应的组合物化学发光分析方法的灵敏度和检测上限，结果如表2所示。
表2
Figure PCTCN2019100341-appb-000003
从表2可知，采用通过将小粒径的受体微球和大粒径的受体微球组合后形成的组合物的化学发光分析方法，同时具有高灵敏度和高检测上限(宽检测量程)，展现出大粒径受体微球和小粒径受体微球的优势，与单一粒径的受体微球相比含 有两种以上粒径的微球组合物的性能得到极大的提高。
实施例3：不同粒径受体微球的制备
(一)平均粒径在250nm左右的偶联抗体的受体微球的制备
1.1醛基聚苯乙烯乳胶微球的制备及表征过程
1)准备100ml的三口烧瓶，加入40mmol苯乙烯、5mmol丙烯醛、10ml水，搅拌10min后通N 2 30min；
2)称取0.11g过硫酸铵和0.2g氯化钠，溶于40ml水中配置成水溶液。将该水溶液加入到步骤1的反应体系中，继续通N 2 30min；
3)将反应体系升温至70℃，反应15小时；
4)将反应完成后的乳液冷却至室温，用合适的滤布过滤。得到的乳液用去离子水过次离心沉降清洗，直至离心初的上清液的电导率接近去离子水，然后用水稀释，以乳液形式保存；
5)由纳米粒度仪测得此时乳胶微球粒径的Gaussian分布平均粒径为202.2nm，变异系数(C.V.)＝4.60％，Gaussian分布曲线如图1所示。由电导滴定法测得该乳胶微球醛基含量为280nmol/mg。
1.2发光组合物的填埋过程及表征
1)准备25ml的圆底烧瓶，加入0.1g二甲基噻吩衍生物和0.1g铕(Ⅲ)配合物(MTTA-EU 3+)，10ml 95％乙醇，磁力搅拌，水浴升温至70℃，获得配合物溶液；
2)准备100ml的三口烧瓶，加入10ml 95％乙醇、10ml水和10ml浓度为10％、步骤1.1中获得的醛基聚苯乙烯乳胶微球，磁力搅拌，水浴升温至70℃；
3)将步骤1)中的配合物溶液缓慢滴加至步骤2)中的三口烧瓶中，70℃反应2小时后停止搅拌，自然冷却；
4)将上述乳液离心1小时，30000G，离心后弃去上清液，得到填埋有发光组合物的醛基聚苯乙烯微球。
5)由纳米粒度仪测得此时微球粒径的Gaussian分布平均粒径为204.9nm，变异系数(C.V.)＝5.00％(如图2所示)。
1.3受体微球的表面包被葡聚糖
1)取50mg氨基葡聚糖固体于20mL圆底烧瓶中，加入5mL 50mM/pH＝10碳酸盐缓冲液，30℃避光搅拌溶解；
2)取100mg已制备好的填埋有发光组合物的醛基聚苯乙烯微球，加入到氨基葡聚糖溶液中搅拌2小时；
3)将10mg硼氢化钠溶于0.5mL 50mM/pH＝10碳酸盐缓冲液后滴加到上述反应液中，30℃避光反应过夜；
4)将反应后的混合液30000G离心后弃去上清液，加入50mM/pH＝10碳酸盐缓冲液超声分散。重复离心清洗三次后用50mM/pH＝10碳酸盐缓冲液定容，使其终浓度为20mg/ml；
5)取100mg醛基葡聚糖固体于20mL圆底烧瓶中，加入5mL 50mM/pH＝10碳酸盐缓冲液，30℃避光搅拌溶解；
6)将上述微球加入到醛基葡聚糖溶液中搅拌2小时；
7)将15mg硼氢化钠溶于0.5mL 50mM/pH＝10碳酸盐缓冲液后滴加到上述反应液中，30℃避光反应过夜；
8)将反应后的混合液30000G离心后弃去上清液，加入50mM/pH＝10碳酸盐缓冲液超声分散。重复离心清洗三次后用50mM/pH＝10碳酸盐缓冲液定容，使其终浓度为20mg/ml。
9)由纳米粒度仪测得此时微球粒径的Gaussian分布平均粒径为241.6nm，变异系数(C.V.)＝12.90％(如图3所示)。
1.4抗体的偶联过程
1)将配对抗体Ⅰ透析至PH值＝10的50mM CB缓冲液，测得浓度为1mg/ml。
2)在2ml离心管中加入0.5ml(3)中获得的受体微球以及0.5ml步骤1)获得的配对抗体Ⅰ，混匀后加入100μl 10mg/ml NaBH 4溶液(50mM CB缓冲液)，2-8℃反应4小时。
3)反应完毕后加入0.5ml 100mg/ml BSA溶液(50mM CB缓冲液)，2-8℃反应2小时。
4)反应完毕后将离心45min，30000G，离心后弃去上清液，用50mM MES缓冲液重新悬浮。重复离心清洗四次，并稀释至终浓度为100μg/ml，获得偶联抗体Ⅰ的受体微球溶液。
5)由纳米粒度仪测得此时微球粒径的Gaussian分布平均粒径值为253.5nm，变异系数(C.V值)＝9.60％(如图4所示)。
(二)平均粒径在110nm左右的偶联抗体的受体微球的制备
制备方法同上述(一)中平均粒径为250nm左右的受体微球的制备过程，由纳米粒度仪测得该受体微球粒径的Gaussian分布(如图5所示)平均粒径值为107.1nm，变异系数(C.V.)＝7.6％。Nicomp分布为单峰(如图6所示)。
(三)平均粒径在350nm左右的偶联PCT抗体的受体微球的制备
制备方法同上述(一)中平均粒径为250nm左右的受体微球的制备过程，由纳米粒度仪测得该受体微球粒径的Gaussian分布(如图7所示)平均粒径值为347.5nm，变异系数(C.V.)＝3.9％，Nicomp分布为单峰(如图8所示)。
实施例4：采用不同粒径的受体微球的化学发光分析方法灵敏度和检测上限的测定
定义灵敏度点为当浓度Cx的信号高于两倍浓度C0的信号，即RLU(Cx)>2RLU(C0)，则对应的检测试剂灵敏度为Cx。定义检测上限点为使用美国临床实验室标准化委员会(NCCLS)评价方案(EP)系列6的文件中的方法确定的范围上限。
(1)将PCT抗原稀释到20pg/ml、30pg/ml、40pg/ml、50pg/ml、60pg/ml、80pg/ml、160pg/ml、500pg/ml、1000pg/ml、5000pg/ml、20000pg/ml、50000pg/ml、100000pg/ml及200000pg/ml的系列浓度，将采用实施例3中制备的分别包含不同平均粒径(110nm、250nm和350nm)偶联PCT抗体Ⅰ的受体微球的受体试剂(浓度为100ug/ml)，然后与相同的生物素标记的PCT单抗2(稀释到2ug/ml)和通用液(含供体微球的试剂)检测上述浓度系列PCT抗原，利用博阳生物科技(上海)有限公司开发的光激化学发光分析系统检测灵敏度和检测上限如表3所示。
表3
Figure PCTCN2019100341-appb-000004
Figure PCTCN2019100341-appb-000005
从表3可知，110nm平均粒径的受体微球的检测上限较高，但是灵敏度较差；而在350nm平均粒径的受体微球有最佳的灵敏度，但是检测上限较低。
(2)将平均粒径110nm偶联PCT抗体Ⅰ的受体微球溶液与平均粒径350nm偶联PCT抗体Ⅰ的受体微球溶液混合后，得到新的受体试剂。新的受体试剂中，受体微球粒径的测定结果如下：
Gaussian分布平均粒径317.7nm，粒径分布变异系数(C.V值)＝37.2％(如图9所示)；
Nicomp分布为双峰：#1：平均粒径103.1nm变异系数(C.V值)＝11.8％；#2：平均粒径328.8nm，粒径分布变异系数(C.V值)＝13.0％(如图10所示)。
将上述新的受体试剂与生物素标记的PCT单抗2(稀释到2ug/ml)和通用液(含供体微球的试剂)检测上述浓度系列PCT抗原，利用博阳生物科技(上海)有限公司开发的光激化学发光分析系统检测灵敏度和检测上限如表4所示。
表4
Figure PCTCN2019100341-appb-000006
从表4可知，适当增加受体微球粒径的不均一性，所述方法的检测性能得到明显提升。
应当注意的是，以上所述的实施例仅用于解释本发明，并不构成对本发明的任何限制。通过参照典型实施例对本发明进行了描述，但应当理解为其中所用的词语为描述性和解释性词汇，而不是限定性词汇。可以按规定在本发明权利要求的范围内对本发明作出修改，以及在不背离本发明的范围和精神内对本发明进行修订。尽管其中描述的本发明涉及特定的方法、材料和实施例，但是并不意味着本发明限于其中公开的特定例，相反，本发明可扩展至其他所有具有相同功能的方法和应用。

Claims (42)

  1. 一种化学发光分析方法，其通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
  2. 根据权利要求1所述的方法，其特征在于，所述方法通过检测待测样品中的两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
  3. 根据权利要求2所述的方法，其特征在于，所述两种不同粒径的受体微球的粒径差值不低于100nm；优选不低于150nm；更优选不低于200nm。
  4. 根据权利要求2或3所述的方法，其特征在于，所述两种不同粒径的受体微球的粒径比选自1:(1.1-10)；优选选自1:(2-8)；更优选选自1:(3-6)。
  5. 根据权利要求1-4中任意一项所述的方法，其特征在于，所述受体微球的使用浓度为1ug/mL-1000ug/mL；优选为10ug/mL-500ug/mL，更优选为10ug/mL-250ug/mL。
  6. 根据权利要求1-5中任意一项所述的方法，其特征在于，所述待测样品中还包括供体微球，所述供体微球能够在激发状态下生成活性氧。
  7. 根据权利要求1-6中任意一项所述的方法，其特征在于，所述方法为均相化学发光分析方法。
  8. 根据权利要求7所述的方法，其特征在于，所述方法包括以下步骤：
    S1，将待测样本与包含至少两种不同粒径的受体微球的试剂a混合后，再与包含供体微球的试剂b混合，从而得到待测样品；
    S2，利用能量或活性化学物与步骤S1中得到的待测样品接触，激发供体产生活性氧；
    S3，通过检测待测样品中的至少两种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
  9. 根据权利要求8所述的方法，其特征在于，所述待测样本利用稀释液稀释后再进行反应。
  10. 根据权利要求1所述的方法，其特征在于，所述方法通过检测待测样品中的三种不同粒径的受体微球与活性氧反应产生的化学发光信号强度来分析判断待测样品中是否包含待测目标分子和/或待测目标分子的浓度。
  11. 根据权利要求1-10中任意一项所述的方法，其特征在于，所述化学发光信号的检测波长为520～620nm。
  12. 根据权利要求8-11中任意一项所述的方法，其特征在于，采用600～700nm的红色激发光进行激光照射。
  13. 根据权利要求1-12中任意一项所述的方法，其特征在于，所述受体微球包括发光组合物和基质，所述发光组合物填充于基质中和/或包被于基质表面。
  14. 根据权利要求13所述的方法，其特征在于，所述发光组合物能够与活性氧反应产生可检测的化学发光信号，其包含化学发光化合物和金属螯合物。
  15. 根据权利要求14所述的方法，其特征在于，所述化学发光化合物选自烯烃化合物，优选选自二甲基噻吩、双丁二酮化合物、二氧杂环己烯、烯醇醚、烯胺、9-亚烷基苍耳烷、9-亚烷基-N-9,10二氢化吖啶、芳基乙醚烯、芳基咪唑和光泽精以及它们的衍生物，更优选选自二甲基噻吩及其衍生物。
  16. 根据权利要求14或15所述的方法，其特征在于，所述金属螯合物的金属是稀土金属或VIII族金属，优选选自铕、铽、镝、钐、锇和钌，更优选选自铕。
  17. 根据权利要求14-16中任意一项所述的方法，其特征在于，所述金属螯合物包含选自下列的螯合剂：MTTA、NHA、BHHT、BHHCT、DPP、TTA、NPPTA、NTA、TOPO、TPPO、BFTA、2,2-二甲基-4-全氟丁酰-3-丁酮(fod)、2,2’-联吡啶(bpy)、联吡啶基羧酸、氮杂冠醚、氮杂穴状配体和三辛基氧化膦以及它们的衍生物。
  18. 根据权利要求14-17中任意一项所述的方法，其特征在于，所述发光化合物是二甲基噻吩的衍生物，所述金属螯合物是铕螯合物。
  19. 根据权利要求13-18中任意一项所述的方法，其特征在于，所述基质选自带、片、棒、管、孔、微滴定板、珠、粒子和微球；优选为珠和微球。
  20. 根据权利要求13-19中任意一项所述的方法，其特征在于，所述基质是磁性或非磁性粒子。
  21. 根据权利要求13-20中任意一项所述的方法，其特征在于，所述不同粒径的受体微球的基质的材质相同或不同。
  22. 根据权利要求13-21中任意一项所述的方法，其特征在于，所述基质材料选自天然的、合成或改性的天然存在的聚合物，其包括但不限于：琼脂糖、纤维素、硝化纤维素、醋酸纤维素、聚氯乙烯、聚苯乙烯、聚乙烯、聚丙烯、聚(4-甲基丁烯)、聚丙烯酰胺、聚甲基丙烯酸酯、聚对苯二甲酸乙二醇酯、尼龙、聚丁酸乙烯或聚丙烯酸酯；优选地，所述基质为聚苯乙烯乳胶微球；进一步优选为羧基和/或醛基化聚苯乙烯乳胶微球。
  23. 根据权利要求13-22中任意一项所述的方法，其特征在于，所述基质的表面直接连接有生物活性物质，所述生物活性物质能够与待测目标分子特异性结合。
  24. 根据权利要求13-23中任意一项所述的方法，其特征在于，所述基质的表面包被包覆层，所述包覆层的表面连接有生物活性物质，所述生物活性物质能够与待测目标分子特异性结合。
  25. 根据权利要求24所述的方法，其特征在于，所述包覆层中的包覆物选自多糖、高分子聚合物或生物大分子，优选为多糖。
  26. 根据权利要求25所述的方法，其特征在于，所述基质的表面包被至少两个连续多糖层的涂层，其中第一多糖层与第二多糖层自发关联。
  27. 根据权利要求26所述的方法，其特征在于，所述连续多糖层中的每一层自发地与前一多糖层中的每一层相关联。
  28. 根据权利要求25-27中任意一项所述的方法，其特征在于，所述多糖具有侧基官能团，所述连续多糖层的所述官能团与所述前一多糖层的所述官能团所带电荷相反。
  29. 根据权利要求25-28中任意一项所述的方法，其特征在于，所述多糖具有侧基官能团，并且所述多糖的所述连续层通过所述连续层的所述官能团与所述前一层的所述官能团之间的反应与所述前一多糖层共价连接。
  30. 根据权利要求29所述的方法，其特征在于，所述连续多糖层的所述官能团在胺官能团和胺反应性官能团之间交替。
  31. 根据权利要求30所述的方法，其特征在于，所述胺反应性官能团是醛基或羧基。
  32. 根据权利要求26-31中任意一项所述的方法，其特征在于，所述第一多糖层自发地与所述载体相关联。
  33. 根据权利要求26-32中任意一项所述的方法，其特征在于，所述涂层的最外一层多糖层具有至少一个侧基官能团。
  34. 根据权利要求26-33中任意一项所述的方法，其特征在于，所述涂层的最外一层多糖层的侧基官能团选自醛基、羧基、巯基、氨基、羟基和马来胺基中的至少一种；优选选自醛基和/或羧基。
  35. 根据权利要求33或34所述的方法，其特征在于，所述涂层的最外一层多糖层的侧基官能团直接地或间接地与生物活性物质连接。
  36. 根据权利要求25-35中任意一项所述的方法，其特征在于，所述多糖选自含有三个或更多个未修饰或修饰的单糖单元的碳水化合物；优选选自葡聚糖、淀粉、糖原、菊粉、果聚糖、甘露聚糖、琼脂糖、半乳聚糖、羧基葡聚糖和氨基葡聚糖；更优选选自葡聚糖、淀粉、糖原和聚核糖。
  37. 根据权利要求13-36中任意一项所述的方法，其特征在于，所述不同粒径的受体微球的基质粒径相同。
  38. 根据权利要求13-36中任意一项所述的方法，其特征在于，所述不同粒径的受体微球的基质粒径不同。
  39. 根据权利要求1-38中任意一项所述的方法，其特征在于，所述活性氧为单线态氧。
  40. 一种利用如权利要求1-39中任意一项所述的方法来检测待测样品中待测目标分子是否存在和/或待测目标分子的浓度的化学发光分析仪。
  41. 根据权利要求40所述的化学发光分析仪，其特征在于，所述化学发光分析仪至少包括如下部分：
    孵育模块，其用于为待测样本和至少两种不同粒径的受体微球混合后发生化学发光反应提供合适的温度环境；
    检测模块，其用于检测受体微球与活性氧反应产生的化学发光信号；
    处理器，其根据检测模块检测到的化学发光信号的情况判断待测样本中是否存在待测目标分子和/或待测目标分子在待测样本中的浓度。
  42. 一种如权利要求1-39中任意一项所述的方法和/或如权利要求40或41所述的化学发光分析仪在检测包括cTnI在内的心肌损伤标志物和/或包括降钙素原在内的炎症标志物中的应用。
PCT/CN2019/100341 2018-08-13 2019-08-13 一种化学发光分析方法及其应用 WO2020034939A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810915152 2018-08-13
CN201810915152.2 2018-08-13

Publications (1)

Publication Number Publication Date
WO2020034939A1 true WO2020034939A1 (zh) 2020-02-20

Family

ID=69525187

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/100341 WO2020034939A1 (zh) 2018-08-13 2019-08-13 一种化学发光分析方法及其应用

Country Status (2)

Country Link
CN (2) CN116500020A (zh)
WO (1) WO2020034939A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114152742A (zh) * 2021-11-30 2022-03-08 深圳市易瑞生物技术股份有限公司 包含磁性发光微球的光激化学发光免疫检测的试剂盒及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111735942A (zh) * 2020-03-03 2020-10-02 浙江卓运生物科技有限公司 一种均相法化学发光检测方法
CN111912839B (zh) * 2020-08-13 2022-10-28 广东药科大学 催化发光反应器、过氧化丁酮的检测装置和检测方法
CN116413256B (zh) * 2023-02-13 2024-05-28 上海索昕生物科技有限公司 用于光激化学发光检测的感光微球的筛选方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553188A (zh) * 2003-06-06 2004-12-08 克 宋 微阵列信号放大方法
CN102735833A (zh) * 2012-07-09 2012-10-17 沃克(天津)生物科技有限公司 甲状腺过氧化物酶抗体均相发光免疫分析试剂盒及其检测方法
WO2013132338A2 (en) * 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
CN104280542A (zh) * 2014-10-21 2015-01-14 南京基蛋生物科技有限公司 基于金属增强发光及纳米粒子标记放大的双增强化学发光免疫分析法
CN105785030A (zh) * 2016-03-09 2016-07-20 博阳生物科技（上海）有限公司 一种血清特异性IgE光激化学发光免疫分析试剂盒
CN105974129A (zh) * 2016-06-13 2016-09-28 南京普朗医疗设备有限公司 一步均相h-fabp检测试剂盒及其制备和使用方法
CN106501506A (zh) * 2016-06-30 2017-03-15 深圳市亚辉龙生物科技股份有限公司 一种抗蛋白酶3抗体IgG化学发光免疫检测试剂盒及其制备方法
CN107044977A (zh) * 2016-06-30 2017-08-15 深圳市亚辉龙生物科技股份有限公司 一种酪氨酸磷酸酶抗体化学发光免疫检测试剂盒及其制备方法
CN107543922A (zh) * 2016-06-27 2018-01-05 北京康华源科技发展有限公司 一种离心层析荧光免疫检测技术及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300684A1 (en) * 2001-10-08 2003-04-09 Barts and The London National Health Service Trust Homogenous ligand binding assay
US20090075397A1 (en) * 2007-09-13 2009-03-19 Academia Sinica Method for characterizing sugar-binding interactions of biomolecules
JP2014081205A (ja) * 2012-10-12 2014-05-08 Fujikura Kasei Co Ltd Ｃ−反応性タンパク質測定用の測定試薬および測定方法
CN104237525B (zh) * 2013-06-24 2016-04-13 北京美康生物技术研究中心有限责任公司 一种用于测定降钙素原的胶乳增强免疫比浊试剂盒及其制备方法和应用
CN103837675B (zh) * 2014-03-07 2016-01-13 天津市南开医院 多组分同时定量分析的均相发光免疫分析方法及其所使用的试剂盒
CN204228713U (zh) * 2014-11-13 2015-03-25 江苏达骏生物科技有限公司 用于d-二聚体检测的检测卡
CN105044330B (zh) * 2015-08-28 2017-12-22 宁波瑞源生物科技有限公司 一种减少体外检测中生物样本假阳性的封闭液及其应用
CN105758835B (zh) * 2016-05-04 2018-03-27 成都爱兴生物科技有限公司 一种均相免疫分析poct检测方法及使用该检测方法的系统
CN111272997A (zh) * 2017-11-27 2020-06-12 科美诊断技术股份有限公司 一种均相免疫检测试剂盒、检测方法及其应用

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1553188A (zh) * 2003-06-06 2004-12-08 克 宋 微阵列信号放大方法
WO2013132338A2 (en) * 2012-03-06 2013-09-12 Calpro As Competitive immunoassay for calprotectin
CN102735833A (zh) * 2012-07-09 2012-10-17 沃克(天津)生物科技有限公司 甲状腺过氧化物酶抗体均相发光免疫分析试剂盒及其检测方法
CN104280542A (zh) * 2014-10-21 2015-01-14 南京基蛋生物科技有限公司 基于金属增强发光及纳米粒子标记放大的双增强化学发光免疫分析法
CN105785030A (zh) * 2016-03-09 2016-07-20 博阳生物科技（上海）有限公司 一种血清特异性IgE光激化学发光免疫分析试剂盒
CN105974129A (zh) * 2016-06-13 2016-09-28 南京普朗医疗设备有限公司 一步均相h-fabp检测试剂盒及其制备和使用方法
CN107543922A (zh) * 2016-06-27 2018-01-05 北京康华源科技发展有限公司 一种离心层析荧光免疫检测技术及其用途
CN106501506A (zh) * 2016-06-30 2017-03-15 深圳市亚辉龙生物科技股份有限公司 一种抗蛋白酶3抗体IgG化学发光免疫检测试剂盒及其制备方法
CN107044977A (zh) * 2016-06-30 2017-08-15 深圳市亚辉龙生物科技股份有限公司 一种酪氨酸磷酸酶抗体化学发光免疫检测试剂盒及其制备方法

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114152742A (zh) * 2021-11-30 2022-03-08 深圳市易瑞生物技术股份有限公司 包含磁性发光微球的光激化学发光免疫检测的试剂盒及其应用
CN114152742B (zh) * 2021-11-30 2024-05-28 深圳市易瑞生物技术股份有限公司 包含磁性发光微球的光激化学发光免疫检测的试剂盒及其应用

Also Published As

Publication number Publication date
CN110823873A (zh) 2020-02-21
CN116500020A (zh) 2023-07-28

Similar Documents

Publication Publication Date Title
WO2020034940A1 (zh) 一种均相化学发光检测试剂盒及其应用
WO2020034939A1 (zh) 一种化学发光分析方法及其应用
WO2020034938A1 (zh) 一种用于化学发光分析的微球组合物及其应用
CN116754757A (zh) 一种用于均相化学发光分析的供体颗粒及其应用
CN110736739A (zh) 一种均相化学发光检测试剂盒及其应用
CN110736737A (zh) 一种用于化学发光检测的微球组合物及其应用
CN110736735A (zh) 一种均相化学发光检测试剂盒及其应用
WO2020252871A1 (zh) 一种用于均相化学发光检测的受体试剂及其应用
WO2020252870A1 (zh) 一种均相化学发光检测方法及其应用
CN110736738A (zh) 一种用于化学发光检测的微球组合物及其应用
CN112240928B (zh) 一种均相化学发光分析的方法及其应用
CN112240930B (zh) 一种均相化学发光分析的方法及其应用
CN113125711B (zh) 一种受体试剂及其应用
CN113125709A (zh) 一种供体试剂及其应用
CN112240936A (zh) 一种供体试剂在诊断主体心肌损伤中的用途
CN112114149A (zh) 一种受体试剂在诊断主体心肌损伤中的用途
CN112240937B (zh) 一种供体试剂在诊断主体感染细菌炎性疾病中的用途
CN112114148A (zh) 一种受体试剂在诊断主体感染细菌炎性疾病中的用途
CN113125701B (zh) 一种均相化学发光检测试剂盒及其应用
CN113125705B (zh) 一种肌红蛋白的均相检测试剂盒及其应用
CN113125703B (zh) 一种肌红蛋白的均相检测试剂盒及其应用
CN113125700B (zh) 一种肌酸激酶同工酶的均相检测试剂盒及其应用
CN113125417A (zh) 一种受体试剂及其应用
CN113125698A (zh) 一种受体试剂及其应用
CN113125702A (zh) 一种均相化学发光检测试剂盒及其应用

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19850052

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 02/06/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19850052

Country of ref document: EP

Kind code of ref document: A1